Plenary Lecture
Plenary Lecture

July 4 (Thu) 10:45 - 11:45 Room 1

Chair: Takashi UEHARA (Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry, andPharmaceutical Sciences, Okayama University)PL

10:45 - 11:45“Dark” Pathways of Protein Transnitrosylation Injure Synapses in
Alzheimer’s Disease: Mechanism and Potential Treatment
Stuart A. LIPTON (Neurodegeneration New Medicines Center and Department of Molecular Medicine, The
Scripps Research Institute, La Jolla, CA, USA)Special Lecture
Special Lecture 1

July 3 (Wed) 9:30 - 10:30 Room 1

Chair: Akihiro ITO (School of Life Sciences, Tokyo University of Pharmacy and Life Sciences)SL1

9:30 - 10:30

Exploring the mode of action of bioactive molecules
Minoru YOSHIDA1, 2 (1RIKEN Center for Sustainable Resource Science, 2Office of University Profesors,
University of Tokyo)

Special Lecture 2

Chair: Takashi UEHARA (Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry, andPharmaceutical Sciences, Okayama University)

SL2

10:45 - 11:45

Immunological memory to toxic aldehydes
Koji UCHIDA (Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences,
The University of Tokyo,)Special Lecture 3

July 4 (Thu) 9:30 - 10:30 Room 1

Chair: Yoshito KUMAGAI (Graduate School of Pharmaceutical Sciences Kyushu University)
SL3

9:30 - 10:30

Molecular Basis of the Oxidative Stress Response and Diseases
Masayuki YAMAMOTO (Tohoku Medical Megabank Organization, Tohoku University)

Special Lecture 4

July 5 (Fri) 9:00 - 10:00 Room 1

Chair: Motohiro NISHIDA (Department of Physiology, Graduate School of Pharmaceutical Sciences, Kyushu University)
SL4

9:00 - 10:00

Data science that prevents adverse events
Shuji KANEKO (Department of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University)

Educational Lecture
Educational Lecture

July 3 (Wed) 13:30 - 14:30 Room 2

Chair: Jun KANNO (National Institute of Health Sciences)EL

13:30 - 14:30

Understanding Current Situation of New Psychoactive (Dangerous; illicit,
quasi-legal) Drugs in Japan, and How Correspond to This Issue
Takemi YOSHIDA (Council for Pharmacists Credentials)

e21

ProgramJuly 3 (Wed) 10:45 - 11:45 Room 1

Symposium
Symposium 1

July 3 (Wed) 9:30 - 11:30 Room 2

Human drug metabolizing enzymes from experimental animal information
Chairs: Hiroshi YAMAZAKI (Showa Pharmaceutical University)
Makiko SHIMIZU (Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University)
S1-1

Identification and analysis of cytochromes P450 in dogs, pigs, cynomolgus
macaques, and tree shrews
Yasuhiro UNO (Joint Faculty of Veterinary Medicine, Kagoshima University)

S1-2

Functional analysis of flavin-containing monooxygenase in animals andhumansMakiko SHIMIZU (Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University)

S1-3

Species-specific differences in drug metabolism: Humanized-liver mice aspredictive models for drug metabolism and toxicity in humans
Shotaro UEHARA (Central Institute for Experimental Medicine and Lifescience)

S1-4

Pharmacokinetic modeling for medicines in humans using humanizedanimal model data
Hiroshi YAMAZAKI (Showa Pharmaceutical University)

9:30 - 10:00

10:00 - 10:30

10:30 - 11:00

11:00 - 11:30

ProgramSymposium 2

July 3 (Wed) 9:30 - 11:30 Room 4

Korea-Japan joint symposium on redox signaling and organ/tissue toxicity
Chairs: Yoshito KUMAGAI (Graduate School of Pharmaceutical Sciences Kyushu University)
Jin HAN (Cardiovascular and Metabolic Disease Center, College of Medicine, Inje University)
Introduction
9:30 - 9:32

S2-1

9:32 - 10:01

Finding NOX2 inhibitors: Targeting regulatory subunits for isoform
selectivity
Moo-Yeol LEE (BK21 FOUR Team, Integrated Research Institute for Drug Development, College of Pharmacy,
Dongguk University)

S2-2

Supersulfide catabolism underlies cardiac vulnerability to ischemic andelectrophilic stressAkiyuki NISHIMURA (Division of Cardiocirculatory Signaling, National Institute for Physiological Sciences)

S2-3

Adaptive cell responses to excess intracellular reactive sulfur speciesinduced stress
Masahiro AKIYAMA (Pharmacological Research Center, Showa University)

S2-4

Novel cardiac and mitochondrial effects of Echinochrome A
Hyoung Kyu KIM (Cardiovascular and Metabolic Disease Center, Inje Unviersity)

10:01 - 10:30

10:30 - 10:59

10:59 - 11:28

Conclusion
11:28 - 11:30

e22

Symposium 3

July 3 (Wed) 9:30 - 11:30 Room 5

Reversibility of chemical-induced lesions from the viewpoint of theJapanese Society of Toxicologic Pathology
Chairs: Tomoya SANO (Takeda Pharmaceutical Company Limited)
Yuki KATO (SHIONOGI & CO., LTD)
Introduction
9:30 - 9:32

S3-1

Overview of reversibility evaluation and recovery group setting in general
toxicity studies
Junko TAKETO (Chugai Pharmaceutical Co., Ltd.)

S3-2

How we interpret the reversibility of vacuolation lesions in the adrenal
cortex?
Ryo D. OBARA (Laboratory for Drug Discovery and Development, Shionogi & Co., Ltd.)

S3-3

Recoverability in Chemical-induced Lung Lesions in Rodents
Shotaro YAMANO (National Institute of Occupational Safety and Health, Japan Organization of Occupational

9:32 - 9:52

9:52 - 10:16

10:16 - 10:40

S3-4

Recovery of gastric mucosal injury -Temporal histopathological findings
after chief cell damage in ratsHironobu YASUNO (Takeda Pharmaceutical Company Limited)

S3-5

Reversibility of lesions induced by low molecular weight anticancer agents
Ayako SAYAMA (Medicinal Safety Research Laboratory, Daiichi Sankyo Co., Ltd.)

10:40 - 11:04

11:04 - 11:28

Conclusion
11:28 - 11:30

Symposium 4

July 3 (Wed) 9:30 - 11:30 Room 7

Biometals Specialty Section Symposium - Immunotoxicity of metals Chairs: D aigo SUMI (Faculty of Pharmaceutical Sciences, Tokushima Bunri University)
Gi-Wook HWANG (Laboratory of Environmental and Health Sciences, Faculty of Pharmaceutical Sciences,
Tohoku Medical and Pharmaceutical University)

Introduction
9:30 - 9:32

S4-1

The toxicity of titanate nanosheets on human monocytes: cell death throughcontrol failure of lysosomal function caused by increase in intracellular
calcium ions
Yasumitsu NISHIMURA (Department of Hygiene, Kawasaki Medical School)

S4-2

The effect of chemical properties of particulate matter on alveolar macrohage
activation : inflammatory versus non-inflammatory particles
Etsushi KURODA (Department of Immunology, School of Medicine, Hyogo Medical University)

S4-3

Macrophage recognition of carbon nanotubes leading to inflammation
Masafumi NAKAYAMA (Laboratory of Immunology and Microbiology, College of Pharmaceutical Sciences,

9:32 - 10:01

10:01 - 10:30

10:30 - 10:59

Ritsumeikan University)

e23

Program

Health and Safety)

S4-4

10:59 - 11:28

Dysfunction of natural killer cells by arsenic
Daigo SUMI (Faculty of Pharmaceutical Sciences, Tokushima Bunri University)

Conclusion
11:28 - 11:30

Symposium 5

July 3 (Wed) 15:30 - 17:30 Room 1

Understanding of toxicity mechanisms and their application to toxicity
evaluation
Chairs: Kouichi YOSHINARI (Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka)
Akinori TAKEMURA (Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University)
Introduction
15:30 - 15:32

S5-1

Understanding the mechanism of liver injury caused by mitochondrial
membrane permeability transition
Akinori TAKEMURA (Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba

S5-2

Establishment an in vitro developmental toxicity testing based on signal
disruption and advancing the understanding of its mechanism
Yusuke OKUBO1, 2 (1Cellular & Molecular Toxicology Division, Biological Safety Research Center, National

15:32 - 16:01

University)

16:01 - 16:30

2

ProgramInstitute of Health Sciences, Institute of Advanced Sciences, Yokohama National University)

S5-3

Evaluation of developmental neurotoxicity due to thyroid hormone
disrupting effects of chemicals: Current status of efforts aimed at developing
new evaluation methods
Tomoya YAMADA (Environmental Health Science Laboratory, Sumitomo Chemical Co., Ltd.)

S5-4

Development of read-across method using in vitro tests based on
carcinogenic mechanisms as an alternative method for rat carcinogenicity
tests
Kouichi YOSHINARI (Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University

16:30 - 16:59

16:59 - 17:28

of Shizuoka)

Conclusion
17:28 - 17:30

e24

Symposium 6

July 3 (Wed) 13:30 - 15:30 Room 3

An attempt to promote interaction between toxidrome and new findings inmolecular toxicology
Chairs: S atoshi KITAJIMA (Division of Cellular & Molecular Toxicology, Center for Biological Safety & Research,
National Institute of Health Sciences)

Manabu SUGITA (Juntendo University Nerima Hospital)
S6-1

MRP1-dependent Extracellular Release of Glutathione Induces
Cardiomyocyte Ferroptosis After Ischemia-Reperfusion
Yoshinori KATSUMATA (Keio University School of Medicine)

S6-2

Percellome Toxicogenomics in the liver and hippocampus of mice after
single oral administration of tetrodotoxin, a pufferfish poison
Satoshi KITAJIMA (Division of Cellular & Molecular Toxicology, Center for Biological Safety & Research,

13:30 - 14:00

14:00 - 14:25

National Institute of Health Sciences)S6-3

14:25 - 14:50

Toxidrome in Acute Poisoning Diagnosis and Treatment
Kentaro KOBAYASHI (Department of Emergency Medicine and Critical Care, National Center for Global
Health and Medicine)

S6-4

14:50 - 15:15

The toxidrome of chemical agent
Katsura HAYAKAWA (Deartment of Critical Care Medicine, Toranomon Hospital)

Discussion
Symposium 7

July 3 (Wed) 15:30 - 17:30 Room 3

Epigenetic regulation by environmental factors
Chairs: Akihiro ITO (School of Life Sciences, Tokyo University of Pharmacy and Life Sciences)
Naoko HATTORI (Institute for Molecular and Cellular Regulation, Gunma University)
Introduction
15:30 - 15:35
Akihiro ITO (School of Life Sciences, Tokyo University of Pharmacy and Life Sciences)
S7-1

Plasticity of epigenetic regulation
Yoichi SHINKAI (Cluster for Pioneering Research, RIKEN)

S7-2

Epigenome alterations in normal tissue ecosystem and their impact on
carcinogenesis
Naoko HATTORI1, 2 (1Institute for Advanced Life Sciences, Hoshi University, 2Institute for Molecular and15:35 - 15:57

15:57 - 16:19

Cellular Regulation, Gunma University)

S7-3

16:19 - 16:41

Intergenerational epigenetic inheritance induced by environmental stress infatherKeisuke YOSHIDA (Department of Bioregulation, Institute for Advanced Medical Sciences, Nippon Medical
School)S7-4

DNA methylation changes in next generation sperm by gestational arsenic
exposure
Takehiro SUZUKI (Health and Environmental Risk Division, National Institute for Environmental Studies, Japan)

S7-5

Associations between early environmental factors and epigenomic changes
in humans.
Tomoko KAWAI (Department of Maternal-Fetal Biology, National Research Institute for Child Health and Development)

16:41 - 17:03

17:03 - 17:25

e25

Program

15:15 - 15:30

Conclusion
17:25 - 17:30
Naoko HATTORI (Institute for Molecular and Cellular Regulation, Gunma University)
Symposium 8

July 3 (Wed) 13:30 - 15:30 Room 4

Korea-Japan joint symposium on organelle toxicity and metabolic diseases
Chairs: Motohiro NISHIDA (Department of Physiology, Graduate School of Pharmaceutical Sciences, Kyushu University)
Sang Geon KIM (College of Pharmacy, Dongguk University)
Introduction
13:30 - 13:32

S8-1

Navigating drug-targetome-phenotype interaction and their translational
implications
HoJeong KWON (Chemical Genomics Leader Research Lab, Department of Biotechnology, Yonsei University)

S8-2

Roles of Gα12 and NEMO in toxicant-induced ferroptosis
Sang Geon KIM (College of Pharmacy, Dongguk University)

S8-3

Cereblon-induced endoplasmic reticulum stress in diabetic cardiomyopathy
Jin HAN (Cardiovascular and Metabolic Disease Center, College of Medicine, Inje University)

S8-4

Systemic glucose metabolism disorders caused by formation of Drp1-filaminprotein complex
Yuri KATO (Department of Physiology, Graduate School of Phamaceutical Sciences, Kyushu University)

13:32 - 14:02

14:02 - 14:32

14:32 - 15:02

15:02 - 15:28

ProgramConclusion
15:28 - 15:30

Symposium 9

July 3 (Wed) 15:30 - 17:30 Room 4[KSOT-JSOT Joint Symposium] Trends and latest findings on PFAS issues
Chairs: G i-Wook HWANG (Laboratory of Environmental and Health Sciences, Faculty of Pharmaceutical Sciences,
Tohoku Medical and Pharmaceutical University)

Hyung Sik KIM (Division of Toxicology, School of Pharmacy, Sungkyunkwan University)
Introduction
15:30 - 15:32

S9-1

15:32 - 16:01

Assessment of biological effects and the potential mode of action of perand polyfluoroalkyl substances in developing zebrafish
Akira KUBOTA1, 2, 3 (1Research Center for Global Agromedicine, Obihiro University of Agriculture and Veterinary
2

3

Medicine, Department of Veterinary Medicine, Obihiro University of Agriculture and Veterinary Medicine, Diagnostic
Center for Animal Health and Food Safety)

S9-2

Risk of PFAS on human health
Shoji F NAKAYAMA (Japan Environment and Children's Study Programme Office, National Institute for

S9-3

Occurrence and Human Exposure of Perfluoroalkyl Substances in South
Korea
Jeong Eun OH (Dept of Environmental Engineering, Pusan National Univerisity)

S9-4

Nephrotoxicity mechanism of perfluorinated compounds PFOA and PFOS in rats
Hyung Sik KIM (Division of Toxicology, School of Pharmacy, Sungkyunkwan University)

16:01 - 16:30

Environmental Studies)

16:30 - 16:59

16:59 - 17:28

e26

Conclusion
17:28 - 17:30

Symposium 10

July 3 (Wed) 13:30 - 15:30 Room 5

Novel biological response systems to various types of oxidative and toxic
stressChairs: Atsushi MATSUZAWA (Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University)
Kotoko ARISAWA (Graduate School of Pharmaceutical Sciences, Tohoku University)
Introduction
13:30 - 13:32
Atsushi MATSUZAWA (Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences,
S10-1

Intracellular magnesium regulation and ROS production by PRL/CNNM
Hiroaki MIKI (Graduate School of Engineering, Kyoto University)

S10-2

The mechanism of ferroptosis control through selenoprotein P-mediatedintracellular selenium metabolism modulation
Kotoko ARISAWA (Graduate School of Pharmaceutical Sciences, Tohoku University)

S10-3

Regulatory mechanisms of the novel oxidative stress-induced cell deathparthanatos by the balance of several post-translational modifications andvarious diseases
Atsushi MATSUZAWA (Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences,

13:32 - 14:01

14:01 - 14:30

14:30 - 14:59

Tohoku University)

S10-4

14:59 - 15:28

Analysis of mechanism of a novel lipid oxidation-dependent cell death,lipoxytosis by lipoxytosis inducer
Hirotaka IMAI (School of Pharmaceytical Sciences, Kitasato University)

Conclusion
15:28 - 15:30
Kotoko ARISAWA (Graduate School of Pharmaceutical Sciences, Tohoku University)
Symposium 11

July 3 (Wed) 13:30 - 15:30 Room 7

Vaccinology from the perspective of immunotoxicology
Chairs: Yasuo YOSHIOKA (RIMD, Osaka University)
Shogo MISUMI (Department of Environmental and Molecular Health Sciences, Faculty of Medical andPharmaceutical Sciences, Kumamoto University)

Introduction
13:30 - 13:33
Yasuo YOSHIOKA (RIMD, Osaka University)
S11-1

Epidemiological research on adverse reactions and adverse events following
immunization
Wakaba FUKUSHIMA (Department of Public Health, Graduate School of Medicine, Osaka Metropolitan University)

S11-2

Toward the development of mRNA-LNP vaccines with reduced adverse
reactionsYasuo YOSHIOKA1, 2, 3, 4, 5, 6, 7 (1RIMD, Osaka University, 2OTRI, Osaka University, 3Graduate School of

13:33 - 14:00

14:00 - 14:17

4

5

6

Pharmaceutical Sciences, Osaka University, CAMaD, Osaka University, CiDER, Osaka University, MEI, Osaka
7

University, The Research Foundation for Microbial Diseases of Osaka University (BIKEN))

e27

Program

Tohoku University)

S11-3

Immune profiling for understanding the immunogenicity and reactogenicityof new vaccine platforms
Yoshimasa TAKAHASHI (Research Center for Drug and Vaccine Development, National Institute of

S11-4

Role of extracellular vesicles in an inactivated whole virus particle influenza
vaccine and control of side effects
Shogo MISUMI (Department of Environmental and Molecular Health Sciences, Faculty of Medical and

14:17 - 14:44

Infectious Diseases)

14:44 - 15:01

Pharmaceutical Sciences, Kumamoto University)

S11-5

15:01 - 15:28

Science and design to separate immunotoxicity from vaccine adjuvant
efficacy
Ken J ISHII (Division of Vaccine Science, The Institute of Medical Science, The University of Tokyo)

Conclusion
15:28 - 15:30
Shogo MISUMI (Department of Environmental and Molecular Health Sciences, Faculty of Medical andPharmaceutical Sciences, Kumamoto University)

Symposium 12

July 3 (Wed) 15:30 - 17:30 Room 7

Potential of Occupational Pharmacists
Chairs: H ideko SONE (Yokohama University of Pharmacy)
Yusuke KIMURA (Department of Environmental and Preventive Medicine, School of Medicine, Jichi Medical University)
Introduction
Program

15:30 - 15:31

S12-1

Potential of occupational pharmacists
Gaku ICHIHARA (Tokyo University of Science)

S12-2

Self-regulation in chemical management at industrial sites
Akiyoshi ITO (National Institute of Occupational Safety and Health, Japan)

S12-3

The Role of Industrial Pharmacists in Companies
Junya WAKU (Science Center of Industrial Hygiene , Panasonic Health Insurance Organization)

S12-4

The insurance pharmacy pharmacist as a key component of chemical
management in the community
Yoichi ARIMURA (Silky Pharmacy Matrix Co., Ltd.)

S12-5

Occupational health in pharmaceutical education and interest in industrial
pharmacists
Daichi NAGASHIMA1, 2 (1Laboratory of Clinical Pharmaceutics, Yokohama University of Pharmacy,

15:31 - 15:36

15:36 - 15:56

15:56 - 16:16

16:16 - 16:31

16:31 - 16:46

2

General Health Medical Research Center, Yokohama University of Pharmacy)

Panelist
16:46 - 16:56

Yuko YAMANO (Department of Hygiene, Public Health and Preventive Medicine Showa University, School of
Medicine)

Discussion
16:56 - 17:29

Conclusion
17:29 - 17:30

e28

Symposium 13

July 4 (Thu) 9:00 - 11:30 Room 3

Artifical Intelligence (AI) and Biomedical Science and Toxicology.
Chairs: M asatoshi HAGIWARA (Department of Drug Discovery Medicine, Kyoto University)
Jun KANNO (National Institute of Health Sciences)
Introduction
9:00 - 9:03

S13-1

Impact of Artificial Intelligence and Automated Robotics Experimental
Systems for Biomedical Sciences
Hiroaki KITANO (Okinawa Institute of Science and Technology Graduate School, The Systems Biology Institute)

S13-2

AI x Genome x Splicing Regulatory Compounds = Preemptive Medicine
Masatoshi HAGIWARA (Department of Drug Discovery Medicine, Kyoto University)

S13-3

Biomedicine and Toxicology as Collaboration with AI
Yayoi NATSUME-KITATANI1, 2 (1National Institutes of Biomedical Innovation, Health and Nutrition,

9:03 - 9:38

9:38 - 10:13

10:13 - 10:48

2

S13-4

10:48 - 11:23

Tokushima University)

ToxEye: In visio models for toxicogenomics data
Samik GHOSH (The Systems Biology Institute)

Conclusion
Symposium 14

July 4 (Thu) 9:00 - 11:00 Room 4

Seminar for researchers leading toward a new era: Reproducing living
tissues outside the body - Towards understanding its functions and its
applications Chairs: Chika YAMAMOTO (Toho University)
Makoto MIYAUCHI (Basic and Generic Research Department, FineToday Co., Ltd.)
Introduction
9:00 - 9:06

S14-1

Connecting Neural Organoids to Mimic Circuits
Yoshiho IKEUCHI (Institute of Industrial Science, The University of Tokyo)

S14-2

Microdevice-based vascular model
Kae SATO (Department of Chemical and Biological Sciences, Faculty of Science, Japan Women's University)

S14-3

Toward reconstruction of human lung tissue using iPS cells
Shimpei GOTOH (Center for iPS Cell Research and Application, Kyoto University)

9:06 - 9:42

9:42 - 10:18

10:18 - 10:54

Conclusion
10:54 - 11:00

e29

Program

11:23 - 11:30

Symposium 15

July 4 (Thu) 9:00 - 11:30 Room 5

Bird Lead Poisoning: A Health Hazard Happening "Now" in Japan
Chairs: M ayumi ISHIZUKA (Faculty of Veterinary Medicine, Hokkaido University)
Masahiko SATOH (Laboratory of Pharmaceutical Health Sciences, School of Pharmacy, Aichi Gakuin University)
S15-1

What is lead poisoning in birds?
Mayumi ISHIZUKA (Faculty of Veterinary Medicine, Hokkaido University)

S15-2

Current situation of lead (Pb) pollution of wild bird in Japan, focusing on
wild waterfowls
Mitsuki KONDO (Division of Biodiversity ,National Institute for Environmental Studies)

S15-3

Assessment of lead exposure risk for raptors distributed in Honshu using
hunting statistics data
Manabu ONUMA (Biodiversity Division, National Institute for Environmental Studies)

S15-4

Characteristics of lead toxicity and species differences in birds
Shouta NAKAYAMA1, 2 (1Laboratory of Toxicology, Faculty of Veterinary Medicine, Hokkaido University,

9:00 - 9:10

9:10 - 9:45

9:45 - 10:20

10:20 - 10:55

2

S15-5

10:55 - 11:30

School of Veterinary Medicine, The University of Zambia)

What's wrong with lead poisoning in wild birds? ~Focusing on rare birds ofprey and waterfowl~
Keisuke SAITO (Institute for Raptor Biomedicine Japan)

ProgramSymposium 16

July 4 (Thu) 9:00 - 11:00 Room 6

Issues and Initiatives for Safety Evaluation of Oligonucleotide Therapeutics
Chairs: M aya KIMURA (Takeda Pharmaceutical Company Limited)
Yuko NAGAYAMA (Global Drug Safety, Eisai Co., Ltd.)
Introduction
9:00 - 9:05

S16-1

Challenges and Efforts to Evaluate Innate Immune Activation in
Oligonucleotide Therapeutics
Chinami ARUGA (Mitsubishi Tanabe Pharma Corporation)

S16-2

Establishing an in vitro complement-activation assessment system witholigonucleotide therapeutics-- Collaborative Study of the Consortium for
Safety Evaluation of Oligonucleotide Therapeutics-Akihito YAMASHITA (Astellas Pharma, Inc.)

S16-3

Safety evaluation challenges in nucleic acid drug development (developmentof viltolarsen)
Tomohiko HANADA (Safety Assessment Department, Discovery Research Laboratories, Nippon Shinyaku Co., Ltd.)

S16-4

Preliminary studies of in vitro/vivo convulsion evaluation in drug
development for nucleic acid drugs
Motohiro SHIOTANI (Global Drug Safety, Eisai Co., Ltd.)

9:05 - 9:30

9:30 - 9:55

9:55 - 10:30

10:30 - 10:55

Conclusion
10:55 - 11:00

e30

Symposium 17

July 4 (Thu) 15:00 - 17:00 Room 2

Biometric analysis technology linked to morphology
Chairs: Makoto SHIBUTANI (Tokyo University of Agriculture and Technology Graduate School, Institute of Agriculture Science)
Yuji ISHII (Division of Pathology, National Institute of Health Sciences)
S17-1

Application of mass spectrometry imaging to safety research.
Yuji ISHII (Division of Pathology, National Institute of Health Sciences)

S17-2

Importance of quantitative local imaging in drug discovery for diversified
therapeutic modalities
Masataka OITATE (Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo)

S17-3

Proteomic analysis technology for pathological elucidation using FFPE
tissue samples
Tomoaki MURAKAMI (Laboratory of Veterinary Toxicology, Tokyo University of Agriculture and Technology)

S17-4

High-Resolution and High-Depth Spatial Transcriptome Profiling in
Microstructures
Mizuki HONDA1, 2 (1Graduate School of Integrated Sciences for Life, Hiroshima University, 2Graduate School

15:00 - 15:30

15:30 - 16:00

16:00 - 16:30

16:30 - 17:00

of Medicine, Kyoto University)

Symposium 18

July 4 (Thu) 15:00 - 17:00 Room 3

Intestinal Toxicology
ProgramChairs: H iroshi ONODERA (National Institute of Health Sciences)
Yasuko SAKAGUCHI (Kyowa Kirin Co., Ltd.)
Introduction
15:00 - 15:05

S18-1

Development of microphysiological systems (MPS) that recapitulate thesmall intestine function for ADMET research
Hiroyuki KUSUHARA (Graduate School of Pharmaceutical Sciences, the University of Tokyo)

S18-2

Effects of differences by species, region, and developmental stage/aging on
gastrointestinal toxicity
Masako IMAOKA (Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd.)

S18-3

Investigation of predictivity by non-clinical toxicity studies ongastrointestinal adverse events observed in the clinical trials of new drugs
Akio KOBAYASHI (Department of Pharmaceutical Sciences, International University of Health and Welfare)

S18-4

Clinical gastrointestinal toxicity based on epidemiological data
Mutsuhiro IKUMA (Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency)

S18-5

Development of highly functional human intestinal model for pharmaceuticalresearch
Hiroyuki MIZUGUCHI1, 2, 3, 4, 5 (1Laboratory of Biochemistry and Molecular Biology, Graduate School

15:05 - 15:28

15:28 - 15:51

15:51 - 16:14

16:14 - 16:37

16:37 - 17:00

2of Pharmaceutical Sciences, Osaka University., National Institute of Biomedical Innovation, Health and Nutrition,
3

Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research
45

Initiatives, Osaka University, Global Center for Medical Engineering and Informatics, Osaka University, Center for
Infectious Disease Education and Research, Osaka University)e31Symposium 19

July 4 (Thu) 15:00 - 17:00 Room 4

Disruption of the circadian clock underlying health disorders and diseases:
towards an understanding of the mechanisms and the development ofpreventive strategies
Chairs: S atoru KOYANAGI (Depaetment of Pharmaceutics, Faculty of Pharmaceutical Sciences, Kyushu University)
Kentaro USHIJIMA (Division of Pharmaceutics, Faculty of Pharmacuetical Sciences, Sanyo-Onoda City University)
S19-1

The molecular mechanism of cellular oncogenesis and acquisition of drug
resistance through modulation of circadian clock function
Satoru KOYANAGI (Depaetment of Pharmaceutics, Faculty of Pharmaceutical Sciences, Kyushu University)

S19-2

Circadian clock regulates severity of allergic disease symptoms
Yuki NAKAMURA (Department of Immunology, Graduate of School of Medicine, University of Yamanashi)

S19-3

Sex-dependent effect of aberrant lighting conditions on circadian clock andmetabolism
Shinobu YASUO (Faculty of Agriculture, Kyushu University)

S19-4

Biomarkers of Osteoarthritis Explored by Biological Clock Disorders
Kentaro USHIJIMA1, 2 (1Division of Pharmaceutics, Faculty of Pharmacuetical Sciences, Sanyo-Onoda City

15:00 - 15:30

15:30 - 16:00

16:00 - 16:30

16:30 - 17:00

2

University, Division of Clinical Pharmacology, Jichi Medical University)

Symposium 20

July 4 (Thu) 15:00 - 17:00 Room 5

ProgramCutting Edge of Metallomics in Toxicology "New Developments in IndustryGovernment-Academia Collaboration"
Chairs: Yu-ki TANAKA (Graduate School of Pharmaceutical Sciences, Chiba University)
Miyuki IWAI-SHIMADA (National Institute for Environmental Studies)
Introduction
15:00 - 15:02

S20-1

Development of analytical method for nanomaterials using asymmetric flow
field-flow fractionation (AF4) coupled with inductively coupled plasma mass
spectrometry
Yu-ki TANAKA ( Graduate School of Pharmaceutical Sciences, Chiba University)

S20-2

Instrumental Analysis - ICP Mass Spectrometry - in Metallomics Research
Kyoko KOBAYASHI (PerkinElmer Japan G.K.)

S20-3

Principle and technical introduction of LA-ICP-MS for multifaceted analysis
of elemental information in biological samples
Yasuo KUROKI (Application Group, Elemental Dept, Thermo Fisher Scientific K.K.)

S20-4

Industry-government-academia collaboration from epidemiological studies:trends in metallomics research
Miyuki IWAI-SHIMADA (National Institute for Environmental Studies)

15:02 - 15:31

15:31 - 16:00

16:00 - 16:29

16:29 - 16:58

Conclusion
16:58 - 17:00

e32

Symposium 21

July 4 (Thu) 15:00 - 17:00 Room 6

Data science develops the new future for drug toxicology
Chairs: Shuji KANEKO (Department of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto University)
Yoshito ZAMAMI (Department of Pharmacy, Okayama University Hospital)
Opening Remarks
15:00 - 15:04

S21-1

Advancing drug evaluation using big data analysis
Yasunari KANDA (Division of Pharmacology, National Institute of Health Sciences)

S21-2

Quantitative prediction of pharmacological activities from chemical
structures by graph convolutional neural network
Kazuki NAGAYASU (Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences,

S21-3

Drug Toxicity Assessment Utilizing Clinical Information and Genetic Data
Databases
Hirofumi HAMANO (Department of Pharmacy, Okayama University Hospital)

S21-4

Challenges in evaluating drug safety using real-world database
Sachiko TANAKA-MIZUNO (Laboratory of Epidemiology and Prevention, Kobe Pharmaceutical University)

15:04 - 15:32

15:32 - 16:00

Kyoto University)

16:00 - 16:28

16:28 - 16:56

Closing Remarks
Symposium 22

July 4 (Thu) 15:00 - 17:00 Room 7

Drug induced seizure assessment in drug development - improvement of
nonclinical sizure risk assessment
Chairs: M otohiro SHIOTANI (Global Drug Safety, Eisai Co., Ltd.)
Takafumi SHIRAKAWA (Non-clinical Regulatory Science, Astellas Pharma Inc.)
S22-1

Introduction: Assessment of drug-induced convulsion in drug development
Motohiro SHIOTANI (Global Drug Safety, Eisai Co., Ltd.)

S22-2

Challenge to develop an in vitro MEA test to predict in vivo seizure risk
Norimasa MIYAMOTO1, 2 (1Advanced Biosignal Safety Assessment, Biopharmaceutical Assessment Unit,

15:00 - 15:12

15:12 - 15:39

2

Eisai Co., Ltd., Laboratory of Genomics-based Drug Discovery, Faculty of Medicine, University of Tsukuba)

S22-3

Prediction of drug-induced seizure using rat EEG
Kenichi KINOSHITA (Targeted Protein Degradation, Astellas Pharma Inc.)

S22-4

Prediction of Seizure Liability and Mechanism of Action Using Human iPSCDerived Neuronal Cells and Astrocytes
Ikuro SUZUKI (Department of electronics, Tohoku Institute of technology)

S22-5

Drug-induced convulsions: Overview from Clinical Department
Riki MATSUMOTO (Division of Neurology, Kobe University Graduate School of Medicine)

15:39 - 16:06

16:06 - 16:33

16:33 - 17:00

e33

Program

16:56 - 17:00

Symposium 23

July 5 (Fri) 10:00 - 12:00 Room 1

Children’s Toxicology: Research findings on the mechanism of modificationof higher brain function by perinatal chemical exposure and their biologicalrelevance to reported findings in human children.
Chairs: J un KANNO (National Institute of Health Sciences)
Kentaro TANEMURA (Laboratory of Animal Reproduction and Development Graduate School of
Agricultural Science Tohoku University)

Opening Remarks
10:00 - 10:02
Jun KANNO (National Institute of Health Sciences)S23-1

Introduction
Jun KANNO (National Institute of Health Sciences)S23-2

Mechanism of aberrant brain development induced by exposure to thereverse transcriptase inhibitor during fetal stages
Kinichi NAKASHIMA (Graduate School of Medical Sciences, Kyushu University)

S23-3

Step-by-step neuronal development and the AUTS2 syndrome
Mikio HOSHINO (National Institute of Neuroscience, NCNP)

S23-4

Is prenatal exposure to PFASs associated with neurodevelopmental delay
and the emergence of neurodevelopmental disorders?
Kenji J TSUCHIYA1, 2 (1Research Center for Child Mental Development, Hamamatsu University School of

10:02 - 10:07

10:07 - 10:32

10:32 - 10:57

10:57 - 11:22

Program2

Medicine, Osaka University United Graduate School of Child Development)

S23-5

11:22 - 11:47

Effects of early-life tosufloxacin tosilate hydrate administration on growthrate, and neurobehavior at adulthood in male mice
Kentaro TANEMURA (Laboratory of Animal Reproduction and Development Graduate School of
Agricultural Science Tohoku University)

Discussion
11:47 - 11:57

Closing Remarks
11:57 - 12:00
Jun KANNO (National Institute of Health Sciences)e34Symposium 24

July 5 (Fri) 9:00 - 11:00 Room 2

Unravel the mechanism of action of bioactive substances/environmental
chemicals by instrumental analysis.
Chairs: N aoshi DOHMAE (RIKEN Center for Sustainable Resource Science)
Takahiro SHIBATA (Graduate School of Bioagricultural Sciences, Nagoya University)
S24-1

Analysis of the effects of bioactive and environmental chemicals on livingorganisms by proteomics.
Naoshi DOHMAE (RIKEN Center for Sustainable Resource Science)

S24-2

Ultra-deep proteomics by DIA-MS
Yusuke KAWASHIMA (Kazusa DNA Research Institute)

S24-3

Protein adductome analysis using mass spectrometry
Takahiro SHIBATA1, 2, 3 (1Graduate School of Bioagricultural Sciences, Nagoya University, 2Institute of Nano-

9:00 - 9:30

9:30 - 10:00

10:00 - 10:30

3Life-Systems, Institutes of Innovation for Future Society, Nagoya University, Institute for Glyco-core Research(iGCORE), Nagoya University)

S24-4

10:30 - 11:00

Infection and inflammation control approaching by supersulfidomics
Tomohiro SAWA (Department of Microbiology, Graduate School of Medical Sciences, Kumamoto University)

Symposium 25

July 5 (Fri) 9:00 - 11:30 Room 3

SOT-JSOT Joint Symposium: NAMs and Risk Assessment
ProgramChairs: Akihiko HIROSE (Chemicals Evaluation and Research Institute, Japan)
Introduction
9:00 - 9:05
Akihiko HIROSE (Chemicals Evaluation and Research Institute, Japan)
S25-1
9:05 - 9:40

Development and future challenges in integrating in silico approaches tosupport regulatory decisions in chemical risk assessment
Takashi YAMADA (Division of Risk Assessment, Center of Biological Safety and Research, National Instituteof Health Sciences)

S25-2【Video Lecture】Using NAMs to inform mode of action and human relevancein chemical safety assessment: A case-study involving PFAS
Laurie C. HAWS (ToxStrategies LLC)

S25-3

Challenges and Perspectives in Utilizing New Approach Methodologies(NAMs) for Food Safety Assessments
Atsushi ONO (Laboratory of Toxicology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,

9:40 - 10:15

10:15 - 10:50

Division of Pharmaceutical Sciences, Okayama University)

S25-4

10:50 - 11:25

Learning by Doing: Gaining confidence in new approaches for regulatory
decision-making and risk assessment
Kristie M. SULLIVAN (Institute for In Vitro Sciences)

Conclusion
11:25 - 11:30
Akihiko HIROSE (Chemicals Evaluation and Research Institute, Japan)

e35

Symposium 26

July 5 (Fri) 9:00 - 11:00 Room 4

Glial Crosstalk in Neurological Disorders
Chairs: Masato ASANUMA (Department of Medical Neurobiology, Okayama University Graduate School of
Medicine, Dentistry and Pharmaceutical Sciences)

Eiji SHIGETOMI (Yamanashi GLIA Center, Interdisciplinary Graduate School of Medicine, University of Yamanashi)
Overview
9:00 - 9:10
Eiji SHIGETOMI (Yamanashi GLIA Center, Interdisciplinary Graduate School of Medicine, University of
Yamanashi)

S26-1
9:10 - 9:35

Neuronal hyper-excitability through an excitatory molecule derived fromreactive astrocytes.
Eiji SHIGETOMI1, 2 (1Yamanashi GLIA Center, Interdisciplinary Graduate School of Medicine, University
2of Yamanashi, Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of
Yamanashi)

S26-2
9:35 - 10:00

Mechanism of chronic pain after nerve injury from the viewpoint of microglia
Makoto TSUDA (Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical
Sciences, Kyushu University)

S26-3

Possibility of oxytocin as a treatment for stroke sequelae through thephenotypic control effect of activated microglia
Youichirou HIGASHI (Department of Pharmacology, Kochi Medical School, Kochi University)

S26-4

Neuron-glia crosstalk in Parkinson’s disease
Ikuko MIYAZAKI (Department of Medical Neurobiology, Okayama University Graduate School of Medicine,

10:00 - 10:25

Program

10:25 - 10:50

Dentistry and Pharmaceutical Sciences)

Conclusion
10:50 - 10:55
Masato ASANUMA (Department of Medical Neurobiology, Okayama University Graduate School of
Medicine, Dentistry and Pharmaceutical Sciences)

Eiji SHIGETOMI (Yamanashi GLIA Center, Interdisciplinary Graduate School of Medicine, University of
Yamanashi)

Symposium 27

July 5 (Fri) 9:00 - 11:00 Room 5

Current situation and issues in regulatory and industrial acceptance of MPS
Chairs: H itoshi NARAOKA (Astellas Pharma Inc.)
Kaoru SATO (National Institute of Health Sciences)S27-1
9:00 - 9:30

Current status and issues of regulatory acceptance of microphysiologicalsystems
Seiichi ISHIDA1, 2 (1Division of Applied Life Science, Graduate School of Engineering, Sojo University,
2

National Institute of Health Sciences)S27-2

Research on MPS at the Joint Center - Toward robust technologyYuzuru ITO (Faculty of Life and Environmental sciences, University of Tsukuba)

S27-3

Improving Predictive Toxicology with Organ-Chips and Continuous Innovation
Haruka HISADA (FUJIFILM Wako Pure Chemical Corporation. )S27-4

Use of Microphysiological systems at CRO
Yoshiaki SUWA1, 2 (1Shin Nippon Biomedical Laboratories, Ltd., 2Institute of Life and Environmental Sciences,

9:30 - 10:00

10:00 - 10:30

10:30 - 11:00

University of Tsukuba)e36Symposium 28

July 5 (Fri) 9:00 - 11:00 Room 6

Unity in diversity: Adducts-linked Toxicology
Chairs: Keiko TAGUCHI (Laboratory of Food Chemistry, Graduate School of Agricultural and Life Sciences, The
University of Tokyo)

Yumi ABIKO (Nagasaki University)
Introduction
9:00 - 9:03

S28-1

Activation of redox signaling pathways by environmental chemicals throughadduct formation with sensor proteins
Yumi ABIKO (Graduate School of Biomedical Sciences, Nagasaki University)

S28-2

Metabolic remodeling of selenium through adduct formation of selenoprotein P
Takashi TOYAMA (Laboratory of Molecular Biology and Metabolism, Graduate School of Pharmaceutical

9:03 - 9:26

9:26 - 9:49

S28-3

Aberrant protein S-nitrosylation contributes to synaptic impairment andneuronal damage in neurodegenerative diseases
Tomohiro NAKAMURA (Department of Molecular Medicine, The Scripps Research Institute)

S28-4

Post-translational modifications induced by food additives.
Kota NORITSUGU (School of Life Sciences, Tokyo University of Pharmacy and Life Sciences)

S28-5

Adduct formation in the KEAP1-NRF2 system
Keiko TAGUCHI (Laboratory of Food Chemistry, Graduate School of Agricultural and Life Sciences, The

9:49 - 10:12

10:12 - 10:35

10:35 - 10:58

Program

Sciences, Tohoku University)

University of Tokyo)

Conclusion
10:58 - 11:00

Symposium 29

July 5 (Fri) 9:00 - 11:00 Room 7

PDE/OEL setting by toxicologist - For qulity control of pharmaceuticals andworker safety Chairs: Shoji ASAKURA (Global Drug Safety, Eisai Co., Ltd.)Kiyohiro HASHIMOTO (Takeda Pharmaceutical, Research, Drug Safety Research and Evaluation)
Introduction
9:00 - 9:02

S29-1

PDE and OEL in the Pharmaceutical Industry
Yukako ISHITSUKA (JAPAN NUS. CO., LTD.)

S29-2

How to use PDE/OEL in the pharmaceutical industry
Tomoyuki HASEGAWA (EHS Promotion, Sustainability Promotion Department, ONO Pharmaceutical Co., LTD.)

S29-3

PDE/OEL setting in the pharmaceutical company
Takao KOROOKA (EA Pharma Co., Ltd.)

S29-4

PDE/OEL settings of pharmaceuticals lacking sufficient toxicologicalinformation
Tae HAYASHI (Chemicals Assessment and Research Center)

9:02 - 9:25

9:25 - 9:48

9:48 - 10:11

10:11 - 10:34

e37

S29-5

10:34 - 10:57

Considerations for AI/OEL Calculation of Mutagenic Carcinogens
Kiyohiro HASHIMOTO (Takeda Pharmaceutical, Research, Drug Safety Research and Evaluation)

Conclusion
10:57 - 11:00

Symposium 30

July 5 (Fri) 14:00 - 16:30 Room 1

Current status and future perspectives of drug evaluation toward
personalized medicine.
Chairs: Yasunari KANDA (Division of Pharmacology, National Institute of Health Sciences)
Hiromi SATO (Clinical Pharmacology & Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba
University)

Introduction
14:00 - 14:02
Yasunari KANDA (Division of Pharmacology, National Institute of Health Sciences)S30-1

14:02 - 14:31

Separation of error structures based on clearance classification andindividualized prediction of pharmacokinetics
Hiromi SATO (Clinical Pharmacology & Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba
University)S30-2

14:31 - 15:00

Genetic factors involved in the idiosyncratic serious adverse drug reactions
Ryosuke NAKAMURA1, 2 (1National Institute of Health Sciences, 2Faculty of Pharmaceutical Sciences, Teikyo

Program

University)S30-3

15:00 - 15:29

Gender considerations in toxicity assessment of drugs
Junko KUROKAWA (Department of Bio-Informational Pharmacology, Faculty of Pharmaceutical Sciences,
University of Shizuoka)

S30-4

Non-clinical assessments of efficacy and safety for developing a novel
therapeutic for pediatric heart failure
Hiroyuki KAWAGISHI1, 2 (1National Institute of Health Sciences, 2Shinshu university)

S30-5

Prediction of individual difference via a side effect mechanism
Yasunari KANDA (Division of Pharmacology, National Institute of Health Sciences)

15:29 - 15:58

15:58 - 16:27

Conclusion
16:27 - 16:30
Hiromi SATO (Clinical Pharmacology & Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba
University)e38Symposium 31

July 5 (Fri) 14:00 - 16:00 Room 2

Toxicity and function of short-lived reactive species
Chairs: F umie NAKASHIMA (Graduate School of Bioagricultural Sciences, Nagoya University)
Ken-ichi YAMADA (Department of Molecular Pathobiology, Faculty of Pharmaceutical Sciences, Kyushu University)
S31-1

Oxidative transformation gives function to food-derived low-molecularcompounds
Fumie NAKASHIMA (Graduate School of Bioagricultural Sciences, Nagoya University)

S31-2

Search for functional food ingredients using supersulfide omics analysis
Shingo KASAMATSU (Dept. of Biol. Chem., Grad. Sch. of Sci., Osaka Metropolitan Univ.)

S31-3

Exploring novel oxidized phospholipids to elucidate an exhaustive
understanding of their functions
Mirinthorn JUTANOM (Department of Molecular Pathobiology, Faculty of Pharmaceutical Sciences, Kyushu

14:00 - 14:30

14:30 - 15:00

15:00 - 15:30

University)

15:30 - 16:00

Role of Nrf2 in Cellular Adaptive Response to Reactive Oxygen/NitrogenSpecies and Electrophilic Toxicants: Pros and Cons
Young-Joon SURH (College of Pharmacy, Seoul National University)

Symposium 32

July 5 (Fri) 14:00 - 16:00 Room 3

Career development support program for toxicologists: Technology transfer
and career development in safety research
Chairs: Kouichi YOSHINARI (Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka)
Yukinori AMANO (JSOT Science and Publicity Committee, Kowa Dental Health Co., Ltd.)
Introduction
14:00 - 14:03

S32-1

Efforts for transfer of experimental technique and career development in thepharmaceutical company
Yoshimi TSUCHIYA (Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd.)

S32-2

Human resource development for safety assessment in an agrochemicalcompany: current status and challenges
Kazuya TAKEUCHI (Toxicology & Environmental Science Department, Biological Research Laboratories,

14:03 - 14:23

14:23 - 14:43

Nissan Chemical Corporation)

S32-3

Initiatives of education and training for toxicology researchers in CROs
Hideshi TSUSAKI (Shin Nippon Biomedical Laboratories, Ltd (SNBL))

S32-4

Current Status and Future Issues of Safety Evaluation Education in Partner
Research Organization (PRO)Yoshiyuki FURUKAWA (Axcelead Drug Discovery Partners, Inc.)

14:43 - 15:03

15:03 - 15:23

Discussion
15:23 - 15:58

Conclusion
15:58 - 16:00

e39

Program

S31-4

Symposium 33

July 5 (Fri) 14:00 - 16:00 Room 4

Current Status and Future Prospects of Environmental Risk Assessment ofPharmaceuticals
Chairs: Takashi YAMADA (Division of Risk Assessment, Center of Biological Safety and Research, National Instituteof Health Sciences)

Akihiko HIROSE (Chemicals Evaluation and Research Institute, Japan)
Introduction
14:00 - 14:05

S33-1

Environmental risks of pharmaceuticals and guidance of environmental
impact assessment of newly applied pharmaceuticals in Japan
Tetsuji NISHIMURA (Teikyo Heisei University)

S33-2

Occurrence of 111 Human Pharmaceuticals in Aquatic Environments in Japan
Norihiro KOBAYASHI (National Institute of Health Sciences)

S33-3

Ecotoxicity tests and ecological risk assessment for chemicals including
pharmaceuticals
Hiroshi YAMAMOTO1, 2 (1Division of Health and Environmental Risk, National Institute for Environmental

14:05 - 14:28

14:28 - 14:51

14:51 - 15:14

2

Studies, Graduate School of Frontier Sciences, The University of Tokyo)

S33-4

Development of a database and in silico prediction methods to support theecotoxicity assessment of pharmaceuticals
Takashi YAMADA (Division of Risk Assessment, Center of Biological Safety and Research, National Institute

S33-5

Pharmaceutical industry initiatives for environmental risk assessment (ERA)of human pharmaceuticals – Aspects of ERA for new therapeutic modalities
such as gene therapy products
Keiichiro SATO (EditForce, Inc.)

15:14 - 15:37

Programof Health Sciences)

15:37 - 16:00

Symposium 34

July 5 (Fri) 15:00 - 16:30 Room 5

Peripheral neuropathy caused by cancer chemotherapy drugs: mechanisms
and prevention/treatment
Chair: Makoto TSUDA (Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical
Sciences, Kyushu University)

Introduction
15:00 - 15:03

S34-1

Research on the mechanism of chemotherapy-induced peripheral
neuropathy focusing on myelinating Schwann cells and new researchattempts using a novel sensory nerve organoid
Satoshi IMAI (Department of Medical Pharmacology, School of Pharmaceutical Sciences, Wakayama Medical University)

S34-2

Drug repositioning studies to prevent oxaliplatin-induced peripheral
neuropathy
Takehiro KAWASHIRI (Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of

15:03 - 15:31

15:31 - 15:59

Pharmaceutical Sciences, Kyushu University)e40S34-3

15:59 - 16:27

Mechanisms and risk factors for the development of chemotherapy-induced
peripheral neuropathy
Atsufumi KAWABATA (Laboratory of Pharmacology and Pathophysiology, Faculty of Pharmacy, Kindai University)

Conclusion
16:27 - 16:30

Symposium 35

July 5 (Fri) 15:00 - 16:30 Room 6

Toxicity assessment strategy using advanced in vitro model in drug
discovery
Chairs: Tadahiro SHINOZAWA (Takeda Pharmaceutical Company)
Eri HAMAMURA-YASUNO (Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd.)
S35-1

Current status and issues of safety evaluation in early phase of drug discovery
Hitoshi NARAOKA (Non-clinical Biomedical Scinece, Astellas Pharma Inc.)

S35-2

A strategy for microphysiological system uses in nonclinical safety evaluation
Yudai WATANABE (Astellas Pharma Inc.)

S35-3

Gaps between ideal state and reality of microphysiological system in thesafety evaluation
Kosuke HARADA (Drug Safety Research & Evaluation, Pharmaceutical Research Division, Takeda

15:00 - 15:05

15:05 - 15:25

15:25 - 15:45

S35-4

Evaluation of gastrointestinal toxicity using human intestinal organoids andimage analysis
Yuki SUDO (Translational Research Division, CHUGAI PHARMACEUTICAL CO., LTD.)

S35-5

Selection of complex/simple in vitro evaluation models for efficientunderstanding and mitigation of toxicity
Eri HAMAMURA-YASUNO (Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd.)

15:45 - 16:05

16:05 - 16:25

e41

Program

Pharmaceutical Company Limited)

Workshop
Workshop 1

July 3 (Wed) 9:30 - 11:30 Room 3

Safety considerations and drug development strategies unique to newmodality drugs
Chairs: Tomoyuki MORIYAMA (Global Drug Safety, Eisai Co., Ltd.)
Yuichi TAKAI (Drug Safety Research and Evaluation, Takeda Pharmaceutical Company Limited)
Introduction
9:30 - 9:33

W1-1
9:33 - 9:58

Survey on the development and use of antidotes in new drug modalities
devoid of a concept of “treatment cessation” as risk management
Tomoyuki MORIYAMA1, 2 (1Japan Pharmaceutical Manufacturing Association , 2Global Drug Safety, Eisai
Co., Ltd.)

W1-2【Video Lecture】Protein Degraders in Drug Development: A Safety Perspective
Katie STAMP (Nonclinical Safety Sciences, Bristol Myers Squibb)

W1-3

Nonclinical evaluation of the immunotoxic potential and the immunogenic
potential of antibody drugs with innovative technologies
Chiyomi KUBO (Chugai Pharmaceutical Co., Ltd.)

W1-4

PMDA's Perspective on Non-clinical Safety Assessment of New Modalities
Kazushige MAKI (Pharmaceuticals and Medical Devices Agency)

9:58 - 10:18

10:18 - 10:43

Program

10:43 - 11:08

Discussion
11:08 - 11:27

Conclusion
11:27 - 11:30

Workshop 2

July 3 (Wed) 13:30 - 15:30 Room 1

Frontiers of safety evaluation of drug candidates using human-derived
samples- Toward improved prediction of clinical side effectsChairs: K
 en-ichiro NAN-YA (Toxicological Research Laboratories, Kyowa Kirin Co., Ltd.)
Yoshika IWATA (Chugai Pharmaceutical Co., Ltd.)
Introduction
13:30 - 13:35
Ken-ichiro NAN-YA (Toxicological Research Laboratories, Kyowa Kirin Co., Ltd.)
W2-1

Development of 3D-cultured spheroid model using human renal proximal
tubule epithelial cells for drug discovery
Etsushi TAKAHASHI (R &D Department, Precision Engineering Center, Industrial Division, Nikkiso Co., Ltd.)

W2-2

Usage of Human iPSC-derived Neurons for Neurotoxicity Evaluation in Drug
Discovery
Sho AKAI (Chugai Pharmaceutical Co., Ltd.)

W2-3

Current status and challenges of in vitro evaluation of complement
activation-related pseudoallergy by LNP using human plasma
Natsumi MAEDA (Drug Safety Reserch and Evaluation, Takeda)

13:35 - 13:57

13:57 - 14:19

14:19 - 14:41

e42

W2-4

Development of in vitro cytokine release assay (CRA) and evaluation
strategy for improved clinical predictability
Rie HIRANO (Toxicological Research Laboratories, Kyowa Kirin Co., Ltd.)

W2-5

Mechanistic studies of adaptive immune-mediated drug-induced liver injury(DILI) using drug-specific T-cells in patients
Toru USUI (Preclinical Research Unit, Sumitomo Pharma Co.,LTD.)

14:41 - 15:03

15:03 - 15:25

Conclusion
15:25 - 15:30
Yoshika IWATA (Chugai Pharmaceutical Co., Ltd.)Workshop 3

July 3 (Wed) 15:30 - 17:30 Room 5

Konjaku Monogatari (Tales of Times Now Past) of safety evaluation
technology: Study the old to understand the new
Chairs: M asafumi DOI (Group IV, Hit Discovery Platform Laboratories, Daiichi Sankyo Co., Ltd.)
Nozomi FUJISAWA (Chugai Pharmaceutical Co., Ltd.)
W3-1

Introduction: Evolution of Toxicity Assessment Techniques
Izuru MIYAWAKI (Preclinical Research Unit, Sumitomo Pharma. Co., Ltd.)

W3-2

Novel in vitro neurotoxicity evaluation systems applicable to drug discovery
Takuya KONDO (Preclinical Basic Research, Discovery and Preclinical Research Division, TAIHO

15:30 - 15:42

15:42 - 16:09

W3-3

Current status of the error-corrected next generation sequencing (ecNGS)
Takayoshi SUZUKI (Division of Genome Safety Science, National Institute of Health Sciences )W3-4

Current status of placental MPS research and potential application to
reproductive and developmental toxicity studies
Hirokazu KAJI (Department of Diagnostic and Therapeutic Systems Engineering, Institute of Biomaterials and

16:09 - 16:36

16:36 - 17:03

Bioengineering (IBB), Tokyo Medical and Dental University (TMDU))

W3-5

17:03 - 17:30

Can SGDD make a contribution to Toxicology?
Yoshinori FUJIYOSHI (TMDU Advanced Research Institute, Tokyo Medical and Dental University)

e43

Program

Pharmaceutical Co., Ltd.)Workshop 4

July 4 (Thu) 9:00 - 11:00 Room 2

How do you get the right information from laboratory tests?
Chairs: K umi HONDA (Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd.)
Naoko TANAKA (Terumo Corporation)
Introduction
9:00 - 9:02

W4-1
9:02 - 9:32

Overview of laboratory testing in the non-clinical field: From the viewpoint ofclinical pathology expert
Naoto TOYOTA1, 2 (1Chugai Pharmaceutical Co., Ltd. Translational Research Division, 2Committee on Animal
Clinical Pathology, Japan Society of Clinical Chemistry)

W4-2

Differences in Interpretation Surrounding Clinical Pathology: Speculation ofDiscrepancies Between the Client and the Contractor
Daisuke SASAKI (Astellas Pharma Inc.)

W4-3

Transfer of knowledge on clinical pathology in non-clinical testing: actual
practice at a CRO
Aika KAWABATA (Shin Nippon Biomedical Laboratories (SNBL), Ltd.)

9:32 - 10:02

10:02 - 10:32

Discussion
10:32 - 10:57
Panelists
Naoto TOYOTA (Chugai Pharmaceutical Co., Ltd. Translational Research Division)
ProgramDaisuke SASAKI (Astellas Pharma Inc.)
Aika KAWABATA (Shin Nippon Biomedical Laboratories (SNBL), Ltd.)
Yoshie MANABE (Preclinical Basic Research, TAIHO PHARMACEUTICAL CO., LTD.)
Conclusion
10:57 - 11:00

Workshop 5

July 4 (Thu) 9:00 - 11:00 Room 7

Toxicologic Pathology in the DX Era - Current Issues and Prospects for AI
Pathology Systems and Big Data Chairs: Akira INOMATA (FUJIFILM Toyama Chemical Co., Ltd.)
Etsuko OHTA (Global Drug Safety, Eisai Co., Ltd.)
Opening Remarks
9:00 - 9:02

W5-1

Investigation on the automated histopathology using image recognition models
Makoto SHIRAI (Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd.)

W5-2

Development of AI-driven image analysis⁄pathological diagnosis tool at LifeIntelligence Consortium (LINC)
Yuki KATO (SHIONOGI & CO., LTD)

W5-3

Challenges in AI development for toxicologic pathology from the perspectiveof machine learning engineer
Mitsuru NEGISHI (Imaging & Informatics Laboratories, FUJIFILM Corporation )9:02 - 9:27

9:27 - 9:42

9:42 - 9:57

e44

W5-4

The Practical Implementation of Digital Pathology and AI Pathology Model
Creation
Masaki YAMAZAKI (Safety and Bioscience Research Dept., TR Division, Chugai Pharmaceutical Co., Ltd.)

W5-5

Toxicologic Pathology Goes Digital: European BIGPICTURE Project andEfforts at Boehringer Ingelheim for GLP-Digital Pathology
Yumi KANGAWA (Boehringer Ingelheim, Kobe, Japan)

W5-6

Deep learning for spatial transcriptome with H&E-stained images
Masaru KOIDO (Department of Computational Biology and Medical Sciences, Graduate School of Frontier

9:57 - 10:12

10:12 - 10:27

10:27 - 10:42

Sciences, The University of Tokyo)

Discussion
10:42 - 10:57

Closing Remarks

Program

10:57 - 11:00

e45

Workshop by Young Planning Committee
Workshop by Young Planning Committee 1

July 3 (Wed) 14:30 - 16:00 Room 2

Considering how researchers of childcare generation work
Chairs: Satoshi YOKOTA (Division of Cellular & Molecular Toxicology, Center for Biological Safety & Research,
National Institute of Health Sciences)

Hitomi FUJISHIRO (Faculty of Pharmaceutical Sciences, Tokushima Bunri University)
Y1-1

Takashi UEHARA (Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry, andY1-2

Kazuki TAKEDA (Laboratory of Toxicology, School of Veterinary Medicine, Kitasato University)

Y1-3

Miyuki IWAI-SHIMADA (National Institute for Environmental Studies)

Y1-4

Satoshi YOKOTA (Division of Cellular & Molecular Toxicology, Center for Biological Safety & Research,

Y1-5

Yuki YOSHIZAWA (Sumitomo Pharma Co., Ltd)

Y1-6

Naoko TANAKA (Terumo Corporation)

Y1-7

Keiko KATSUI (Japan Agency for Medical Research and Development)

14:30 - 14:35

14:35 - 14:50

14:50 - 15:00

15:00 - 15:10

15:10 - 15:20

Program

15:20 - 15:30

15:30 - 15:45

Pharmaceutical Sciences, Okayama University)

National Institute of Health Sciences)

Discussion
15:45 - 16:00

e46

Workshop by Young Planning Committee 2

July 3 (Wed) 16:00 - 17:30 Room 2

Tomorrow’s Toxicology Today: Cutting-Edge Technologies for Practical Use
Chairs: F umiyo SAITO (Division of Toxicology, Faculty of Veterinary Medicine, Okayama University of Science)
Kazuki TAKEDA (Laboratory of Toxicology, School of Veterinary Medicine, Kitasato University)
Introduction
16:00 - 16:05
Kazuki TAKEDA (Laboratory of Toxicology, School of Veterinary Medicine, Kitasato University)
Y2-1

AI/Machine Learning in Toxicology ~ Development of toxicity prediction
model for chemical substances ~Kaori AMBE (Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Nagoya City University)

Y2-2

Advances in in vitro evaluation of pharmacokinetics and drug-induced
toxicity using organoid cultures
Hiroshi ARAKAWA (Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences,

16:05 - 16:17

16:17 - 16:29

Y2-3

Odorant in Toxicology ~Elucidation of the direct effects of fragrance
substances on the brain~
Ami OGURO (Graduate School of Biomedical and Health Sciences, Hiroshima University)

Y2-4

Gut bacteria in Toxicology
Masahiro AKIYAMA (Pharmacological Research Center, Showa University)

Y2-5

Liquid-liquid phase separation in Toxicology ~approach from in vitro
experiments~
Chiho WATANABE (Graduate School for Integrated Life Sciences, Hiroshima University)

16:29 - 16:41

16:41 - 16:53

16:53 - 17:05

ProgramKanazawa University)

Booth Session
17:05 - 17:30

e47

Award LectureAward Lecture

July 4 (Thu) 15:00 - 17:05 Room 1

Distinguished Scholar Award
Chair: Takashi UEHARA (Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry, andPharmaceutical Sciences, Okayama University)

AWL1

Deciphering the mysteries of sleep: from basic neuroscience to real-world
applications
Masashi YANAGISAWA (International Institute for Integrative Sleep Medicine (WPI-IIIS), University ofTsukuba)

The JSOT Award
Chair: Satoshi KITAJIMA (Division of Cellular & Molecular Toxicology, Center for Biological Safety & Research,
National Institute of Health Sciences)

AWL2

Understanding of hepatotoxicity mechanisms for chemical risk assessment
Kouichi YOSHINARI (School of Pharmaceutical Sciences, University of Shizuoka)

The Tetsuo Satoh Award
Chair: Yasumitsu OGRA (Graduate School of Pharmaceutical Sciences, Chiba University)
AWL3
ProgramAcademic and society activities in light of the progress of globalization
Yoshito KUMAGAI (Graduate School of Pharmaceutical Sciences, Kyushu University)

The JSOT Young Scientist Award 1
Chair: Yuji ISHII (Graduate School of Pharmaceutical Sciences, Kyushu University)
AWL4

Induction of oxidative stress by various mechanisms: toxicity by Maillard
reaction products and suppression of cytochrome P450 through proteinprotein interaction
Yuu MIYAUCHI (Faculty of Pharmaceutical Sciences, Sojo University)

The JSOT Young Scientist Award 2
Chair: Hisamitsu NAGASE (Department of Pharmacy, Gifu University of Medical Science)
AWL5

Involvement of microRNA against medicine-induced cleft palate
Hiroki YOSHIOKA (Department of Pharmacy, Gifu University of Medical Science)

The JSOT Young Scientist Award 3
Chair: Yoshimi TSUCHIYA (Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd.)
AWL6

e48

Sensitivity differences in drug-induced IgE-independent pseudo-allergic
reactions via Mas-related G-protein coupled receptor X2
Eri HAMAMURA-YASUNO (Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd.)

Candidates for the Excellent Presentation Award (Oral)
Candidates for the Excellent Presentation Award (Oral) 1

July 3 (Wed) 9:30 - 10:36 Room 6

Candidates for the Excellent Presentation Award (Oral) 1
Chairs: M ayumi ISHIZUKA (Faculty of Veterinary Medicine, Hokkaido University)
Ryuichi ONO (Division of Cellular & Molecular Toxicology, Center for Biological Safety and Research (CBSR),
National Institute of Health Sciences (NIHS))

Agricultural Toxicology
P-1E
Mechanisms of disturbance of microglia-neuron interactions induced by
9:30 - 9:36
fipronil metabolites
Tetsushi HIRANO (Faculty of Pharmaceutical Sciences, University of Toyama)
Redox Toxicology
P-3E
Molecular mechanisms underlying anti-ferroptotic role of methylglyoxal
9:36 - 9:42
Takuya NIIJIMA (Lab. of Health Chem., Grad. Sch. of Pharmaceut. Sci., Tohoku Univ.)
P-10E
9:42 - 9:48

Analysis of the role of acyl-CoA synthetase long-chain family member 4 indrug-induced lung injury
Yuki TOMITSUKA (Division of Health Chemistry, Department of Healthcare and Regulatory Sciences, School

P-11E
9:48 - 9:54

Improvement of exercise endurance in mice through hydrogen water intake:antioxidant effects and metabolic improvements
Eika MIZUNO (Doctoral Program in Medical Sciences, University of Tsukuba)

Drug Toxicology
P-15E A quantitative risk assessment of linezolid-associated thrombocytopenia
9:54 - 10:00
based on pharmacokinetic/toxicodynamic simulation
Tetsushu ONITA (Department of Pharmacy, Shimane University Hospital)
P-16E
10:00 - 10:06

Mechanism analysis of vancomycin-induced kidney injury focused on
macrophages and circadian rhythm
Taiki FUKUDA (Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu
University)

P-17E

Visualization of brain distribution of a benzimidazole analog, metonitazene,
in mouse after intraperitoneal administration using desorption electrosprayionization-mass spectrometry imaging (DESI-MSI)
Sakiko NOMURA (Department of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute

P-18E

Multi-Omics approach to identifying gender differences in cisplatin excretionmechanisms in the proximal tubules of the kidney
Satoshi SHIMIZU1, 2 (1Department of Bio-informational Pharmacology, School of Pharmaceutical Sciences,

10:06 - 10:12

of Public Health)10:12 - 10:18

2

University of Shizuoka, Center for SI Medical Research and Department of Laboratory Medicine, The Jikei
University School of Medicine)

P-19E
10:18 - 10:24

Mechanism of bile acid-dependent hepatocyte death by cccDNA modulator
with IFNα-like activity
Akinori TAKEMURA (Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba
University)

e49

Programof Pharmacy, Showa University)P-20E
10:24 - 10:30

Discovery of novel factors responsible for cisplatin renal damage using
cisplatin-resistant proximal tubular cells
Hiroki TAGUCHI (Laboratory of Molecular Nutrition and Toxicology, Graduate School of Pharmaceutical
Sciences, Tokushima Bunri University)

Food Toxicology
P-28E A comprehensive toxicological assessment of trans-fatty acids (TFAs) for
10:30 - 10:36
application to prevention and treatment of TFA-related diseases
Shinnosuke KIMURA (Lab. of Health Chem., Grad. Sch. of Pharmaceut. Sci., Tohoku Univ.)
Candidates for the Excellent Presentation Award (Oral) 2

July 3 (Wed) 10:36 - 11:42 Room 6

Candidates for the Excellent Presentation Award (Oral) 2
Chairs: Yasunari KANDA (Division of Pharmacology, National Institute of Health Sciences)
Takashi TOYAMA (Laboratory of Molecular Biology and Metabolism, Graduate School of Pharmaceutical
Sciences, Tohoku University)

Neuro Toxicology
P-32E AI-based abnormal behavior detection models in cynomolgus monkeys
10:36 - 10:42
Hiroya KONNO (Medichianl Safety Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd.)
P-35E
10:42 - 10:48

Separation of neuronal and astrocytic signals for drug toxicity evaluation in
the central nervous system
Hideaki KURASHIKI (Department of Electronics, Graduate School of Engineering, Tohoku Institute ofProgram

Technology)

P-36E
10:48 - 10:54

Quantitative 3D image analysis of cell death or microglia dynamics in larvalzebrafish brain to test neurotoxicity
Mizuki YUGE (Department of Integrative Pharmacology, Mie University Graduate School of Medicine)

Organelle Toxicology
P-43E The role of hiPSC-derived cardiomyocytes in cardiac safety pharmacology
10:54 - 11:00
study: NEXEL’s Cardiosight®-S and CiPA assay
Ami KIM (Department of Commercializing iPSC Technology, Division of Drug & Cell Cooperative Relation,
NEXEL Co., Ltd., Korea.)

Genetic Toxicology
P-44E Early detection of hepatocarcinogens in rats using γ-H2AX and stem cell
11:00 - 11:06
markers
Mizuho UNEYAMA (Division of Pathology, National Institute of Health Sciences)
P-45E

An indicator of ovulation time in cynomolgus monkeys by ultrasonography
and efforts to improve pregnancy rate
Erise SUGATA (Drug Safety Research Laboratories, Shin Nippon Biomedical Laboratories, Ltd.)

P-48E

Activation of inflammatory responses via inhibition of DNA methylation byenvironmental electrophile 1,2-Naphthoquinone
Tomoki TSUCHIDA (Department of Medicinal Pharmacology, Faculty of Pharmaceutical Sciences, Graduate

11:06 - 11:12

11:12 - 11:18

School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University)e50

P-50E
11:18 - 11:24

Investigation of the involvement of chromosomal rearrangements in thehepatocarcinogenic process of acetamide in rats
Yohei YAMAGAMI1, 2 (1Division of Pathology, National Institute of Health Sciences, 2Laboratory of
Veterinary Toxicology, Tokyo University of Agriculture and Technology)

Environmental Toxicology
P-52E Fundamental study on removal of cadmium using bagasse from aquatic
11:24 - 11:30
environments
Kaito YAMASHIRO1, 2 (1Department of Environmental Health, School of Pharmacy, Tokyo University of2

Pharmacy and Life Sciences, Laboratory of Public Health, Faculty of Pharmacy, Kindai University)

P-53E

Evaluation of estrogenic activity at low doses of bisphenol A using a novelin vivo detection method
Keishi ISHIDA (Laboratory of Hygienic Chemistry and Molecular Toxicology, Gifu Pharmaceutical University)

P-59E

Comparative Assessment of Co-Exposure Effects of the Ferruginous
Components of Subway and Ambient PM with Lipopolysaccharide on
Vascular Function
Oluwatoyin Hannah OWOKONIRAN (Division of Environmental Health, Graduate School of Global

11:30 - 11:36

11:36 - 11:42

Environmental Studies, Kyoto University, Kyoto, Japan)

Candidates for the Excellent Presentation Award (Oral) 3

July 3 (Wed) 13:30 - 14:24 Room 6

Chairs: Yasuhiro ISHIHARA (Graduate School of Integrated Sciences for Life, Hiroshima University)
Makiko KUWAGATA (Teikyo Heisei University)
Chrono Toxicology
P-60E The Relationship Between Heart Failure And Alteration of Circadian Clock in
13:30 - 13:36
Monocyte: A Novel Cardio-renal Interaction
Yuya YOSHIDA (Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu
University)

Pharmacol. Toxicology
P-62E Development of a compound Ames mutagenicity prediction system that
13:36 - 13:42
includes information on mutagenicity strength
Satoshi SUGIYAMA (Imaging & Informatics Laboratories, ICT Strategy Division, FUJIFILM Corporation)
P-64E

Development of read-across method derived from toxicity-specificspace using machine learning technology: Example of multi-class skinsensitization risk assessment
Takaho ASAI (Safety & Analysis, R&D Support, Sunstar Inc.)

P-69E

Development of an Artificial Neural Network Model for Risk Assessment of
Skin Sensitization using ADRA
Kosuke IMAI (SHISEIDO CO., LTD. Brand Value R&D Institute)

P-70E

Establishment of an evaluation system for gastrointestinal toxicity using
human intestinal organoids
Yuki SUDO (Translational Research Division, CHUGAI PHARMACEUTICAL CO., LTD.)

13:42 - 13:48

13:48 - 13:54

13:54 - 14:00

e51

ProgramCandidates for the Excellent Presentation Award (Oral) 3

P-74E

Correlation analysis between structural similarities and NOEL differencesin repeated dose toxicity with Hazard Evaluation Support System Integrated
Platform (HESS) database
Shota NAKAGAWA (Kao Corporation, Safety Science Research)

P-78E

Drug evaluation using Human pluripotent stem cell derived cardiomyocyte
under updated ICH E14/S7B
Eueun KIM (Department of Commercializing iPSC Technology, NEXEL Co., Ltd)

P-89E

Assessment of genotoxicity and carcinogenic potential of animal-based
traditional Chinese medicine
Yun-Rong TSAI (Master Degree Program in Toxicology, College of Pharmacy, Kaohsiung Medical University)

14:00 - 14:06

14:06 - 14:12

14:12 - 14:18

Immuno Toxicology
P-96E Real-world surveillance of immune checkpoint inhibitor-induced immune14:18 - 14:24
related adverse events and their impact on survival outcomes
Ryosuke MATSUKANE (Kyushu University Hospital, Department of Pharmacy)
Candidates for the Excellent Presentation Award (Oral) 4

July 3 (Wed) 14:24 - 15:18 Room 6

Candidates for the Excellent Presentation Award (Oral) 4
Chairs: Tomoki KIMURA (Faculty of Pharmaceutical Sciences, Setsunan University)
Yoshiro SAITO (Graduate School of Pharmaceutical Sciences, Tohoku University)
ProgramDrug Toxicology
P-21E Exploring the advantages and limitations of Zwitterionic Ionic Liquids (ZIL)
14:24 - 14:30
as a novel solvent in in vitro toxicity testing
Yusuke KUBOTA (Suntory Holdings Limited)
Pharmacol. Toxicology
P-22E Construction of an In Vitro Vascular Tolerance Testing System
14:30 - 14:36
Yuki YAMAMURO (Chugai Pharmaceutical Co., Ltd., Translational Research Div.)
Drug Toxicology
P-23E Comparison of a methods for detecting human mesenchymal stem cells
14:36 - 14:42
in mouse tissues in non-clinical studies using quantitative PCR and
immunohistochemical staining
Yuriko YATSUSHIRO (CMIC Pharma Science)
Pharmacol. Toxicology
P-79E Four-week time-course analysis of the pathogenesis of atopic dermatitis
14:42 - 14:48
model induced by MC903 repeated topical application in mice
Yuya HOSHINO (Department of Investigative Toxicology, Preclinical Research, Tokushima Research Center
for Drug Discovery, Otsuka Pharmaceutical Co., Ltd.)

Metallomics Toxicology
P-111E Mechanism of cadmium-induced migration and invasion inhibition in
14:48 - 14:54
extravillous trophoblast HTR-8/SVneo
Shoko OGUSHI (Laboratory of Public Health & Preventive Pharmacology Faculty of Pharmaceutical Sciences,
Setsunan University)e52

Organ Toxicology
P-119E Reversible and monitorable nephrotoxicity in rats by the novel potent
14:54 - 15:00
transcriptional enhanced associate domain (TEAD) inhibitor, K-975
Hironori OTSUKI1, 2 (1Toxicological Research Laboratories, Kyowa Kirin Co., Ltd., 2Laboratory of Molecular
Toxicology, School of Pharmaceutical Sciences, University of Shizuoka)

P-124E Elucidation of the liver pathophysiology of progressive familial intrahepatic
15:00 - 15:06
cholestasis using patient-derived iPS cells
Sayaka DEGUCHI (Center for iPS Cell Research and Application, Kyoto University)
P-126E Establishment of gall bladder organoid derived from cholesteric
15:06 - 15:12
cholelithiasis model mouse and its application
Haru YAMAMOTO (Laboratory of Veterinary Pharmacology, Tokyo University of Agriculture andTechnology)

P-132E Relationship between immunohistochemical changes of vimentin in Sertoli
15:12 - 15:18
cells and spermatogenic defects
Hirokatsu SAITO (Division of Cellular and Molecular Toxicology, Center for Biological Safety and Research,

ProgramNational Institute of Health Sciences)e53

Oral Session
Oral Session 1

July 3 (Wed) 15:30 - 16:18 Room 6

Oral Session 1
Chairs: Tsuyoshi NAKANISHI (Laboratory of Hygienic Chemistry and Molecular Toxicology, Gifu Pharmaceutical University)
Ryota SHIZU (Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka)
Drug Toxicology
O-1
New bioluminescence mechanism by luciferin analogue TokeOni
15:30 - 15:42
Atsushi NAKAMURA1, 2 (1Department of Engineering Science, Graduate School of Informatics and2Engineering, The University of Electro-Communications, Center for Neuroscience and Biomedical Engineering, The
University of Electro-Communications)O-2

Mitochondrial dysfunction associated with cisplatin-induced muscle atrophy
in mouse skeletal muscle
Hiroyasu SAKAI (Department of Biomolecular Pharmacology, Hoshi University)O-3

A case of suspected drug-induced liver injury due to aripiprazole
Noboru HOKAMA (Department of Pharmacy, University of the Ryukyus Hospital)

15:42 - 15:54

15:54 - 16:06

ProgramFood Toxicology
O-5
Method validation of inorganic arsenic using HPLC-ICPMS
16:06 - 16:18
and assessing its contamination in rice sold in Malaysia
Ahmad Faizal ABDULL RAZIS1, 2 (1Department of Food Science, Faculty of Food Science and2Technology, Universiti Putra Malaysia, Malaysia, Laboratory of Food Safety and Food Integrity, Institute of Tropical
Agriculture and Food Security, Universiti Putra Malaysia, Malaysia)

Oral Session 2

July 3 (Wed) 16:30 - 17:30 Room 6

Oral Session 2
Chairs: Akiyuki NISHIMURA (Division of Cardiocirculatory Signaling, National Institute for Physiological Sciences)
Satoshi YOKOTA (Division of Cellular & Molecular Toxicology, Center for Biological Safety & Research,
National Institute of Health Sciences)

Neuro Toxicology
O-6
Neurons in the island of Calleja major are novel targets of dioxin in the
16:30 - 16:42
mouse brain
Eiki KIMURA (Department of Environmental Health, University of Fukui School of Medical Sciences)O-7

16:42 - 16:54

Large-scale voltage-sensitive dye imaging of mouse prefrontal cortex: A new
assay for brain function modulator
Takashi TOMINAGA1, 2, 3 (1Institute of Neuroscience, Tokushima Bunri University, 2Kagawa School of3

Pharmacological Science, Tokushima Bunri University, Graduate School of Pharmaceutical Science, Tokushima
Bunri University)

Organelle Toxicology
O-8
Benzo[a]pyrene and benzo[a]pyrene diol epoxide induce cellular senescence
16:54 - 17:06
in breast cancer cells
Natsuko KITAMOTO (Grad. Sch. Pharm. Sci., Osaka Univ.)

e54

O-9

17:06 - 17:18

Effects of Aldehyde dehydrogenase 1 family member L1 expression
on tetrahydrofolate metabolism and pentose phosphate pathway inhepatocellular carcinoma cell line HuH-7 cells
Masato SASAKI (Division of Infection and Host Defense, Faculty of Pharmaceutical Sciences, Tohoku Medical
and Pharmaceutical University)

Genetic Toxicology
O-10
Detection of genotoxic reactions by analyzing DNA damage response using
17:18 - 17:30
chromatin immunoprecipitation
Katsuyoshi HORIBATA (Division of Genome Safety Science, National Institute of Health Sciences)
Oral Session 3

July 4 (Thu) 11:00 - 11:36 Room 4

Oral Session 3
Chairs: H isaka KURITA (Gifu Pharmaceutical University)
Sho KUBOTA (Department of Medicinal Pharmacology, Faculty of Pharmaceutical Sciences, Graduate Schoolof Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University)

O-12

11:12 - 11:24

Elucidation of the mechanisms by which arsenic compounds induce
parthanatos
Takuya NOGUCHI (Laboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku
University)

O-13

11:24 - 11:36

Glycidamide-formamidopyrimidine derivative induces DNA replication blockand mutagenesis
Jun-ichi AKAGI (Division of Pathology, National Institute of Health Sciences)

Oral Session 4

July 4 (Thu) 11:00 - 11:36 Room 6

Oral Session 4
Chairs: Yasuhiro SHINKAI (Tokyo University of Pharmacy and Life Sciences)
Kotoko ARISAWA (Graduate School of Pharmaceutical Sciences, Tohoku University)
Genetic Toxicology
O-14
Pterostilbene confers endothelial protection under hyperglycemic
11:00 - 11:12
microenvironment through epigenetic regulation of Nrf2
Ramkumar KUNKA MOHANRAM (Professor (Research) Department of Biotechnology School of
Bioengineering SRM Institute of Science and Technology, India)

Environmental Toxicology
O-15
Effects of PFAS exposure on the blood-brain barrier evaluated using a
11:12 - 11:24
human iPS cell-derived BBB model
Yuki FUJIWARA (Department of Integrative Physiology, Gunma University Graduate School of Medicine)
O-16

11:24 - 11:36

Maternal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin causes
developmental disorder of offspring: Aripiprazole restores reduced breast
milk volume, rescuing normal growth
Xing ZOU (Grad Sch Pharmaceut Sci, Kyushu University)

e55

Program

Genetic Toxicology
O-11
Establishing of epigenetic toxicology
11:00 - 11:12
Tohru SHIBUYA (Laboratory of Environmental Epigenetics, Japan)

Oral Session 5

July 4 (Thu) 11:00 - 11:36 Room 7

Oral Session 5
Chairs: Yumi ABIKO (Nagasaki University)
Hirofumi HAMANO (Okayama University Hospital)
Environmental Toxicology
O-17
MBP, a metabolite of bisphenol A, stimulates breast cancer cell malignancy
11:00 - 11:12
via ERβ–GPER1 axis
Masayo HIRAO-SUZUKI (Faculty of Pharmaceutical Sciences, Hiroshima International University)
Pharmacol. Toxicology
O-18
Evaluating the Impact of Loperamide on Irinotecan-Induced Adverse Events:
11:12 - 11:24
A Disproportionality Analysis of the WHO Pharmacovigilance Database(VigiBase)
Tomoaki AKAGI (Department of Hospital Pharmacy Nagasaki University Hospital)
O-19

11:24 - 11:36

Investigation of methods for constructing prediction models for the small
dataset of Cytochrome P450 (CYPs) inhibition using deep learning
Elpri E. PERMADI1, 2 (1Institute for Protein Research, Osaka University, 2Research Center for Pharmaceutical
Ingredients and Traditional Medicine, National Research and Innovation Agency, Indonesia)

Oral Session 6

July 5 (Fri) 11:00 - 11:36 Room 4

Program

Oral Session 6
Chairs: Hiromi SATO (Clinical Pharmacology & Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University)
Tomoki TAKEDA (R&D Group, F-SEEDS CO., LTD.)
Pharmacol. Toxicology
O-20
Machine Learning-Based Drug Screening System Using Human iPS Cell11:00 - 11:12
Derived Cardiomyocytes and Cardiac Tissues to Discover Novel Therapies
for Drug-Induced Cardiotoxicity
Shunsuke FUNAKOSHI (Dept. of Cell Growth and Differentiation, Center for iPS Cell Research andApplication (CiRA), Kyoto University)

O-21

A study on mechanisms of clioquinol (Quinoform)-induced down-regulationof SCO2, a mitochondrial copper chaperone
Masato KATSUYAMA (Radioisotope Center, Kyoto Prefectural University of Medicine)

O-22

Evaluation of an in vitro drug-induced cholestasis model using
cryopreserved human hepatocytes cultured with human hepatocyte-derived
conditioned medium
Yuji ISHIDA1, 2, 3 (1Research and Development Unit, PhoenixBio Co., Ltd., 2Graduate School of Biomedical and11:12 - 11:24

11:24 - 11:36

3

Health Sciences, Hiroshima University, Division of Gastrointestinal and Liver Diseases, Department of Medicine,
Keck School of Medicine, University of Southern California)

e56Oral Session 7

July 5 (Fri) 11:00 - 11:36 Room 5

Oral Session 7
Chairs: N aoko HATTORI (Institute for Molecular and Cellular Regulation, Gunma University)
Hitomi FUJISHIRO (Faculty of Pharmaceutical Sciences, Tokushima Bunri University)
Omics Toxicology
O-23
High-throughput RNA sequencing combined with multiparametric in vitro
11:00 - 11:12
assays for cardiotoxicity risk assessment and mechanistic determination
Paul A WALKER (Cyprotex Discovery Ltd, Department of Toxicology, Alderley Park, Cheshire, UK)
Nano Toxicology
O-24
Synergistic increase in autism spectrum disorder risk from Setd5 gene
11:12 - 11:24
mutation and maternal exposure to carbon black nanoparticle
Atsuto ONODA (Division of Toxicology and Health Science, Faculty of Pharmaceutical Sciences, Sanyo-Onoda
City University)

O-25

11:24 - 11:36

Assessment of Pulmonary Toxicity and Carcinogenicity of Carbon NanoHorns (CNH) and Carbon Nano-Brushes (CNB) Using Intra Tracheal
Instillation in the Rats
Omnia Hosny Mohamed AHMED1, 2, 3 (1Nanotoxicology Project Lab, Nagoya City University, Nagoya,2

Japan, Department of Experimental Pathology and Tumor Biology, Nagoya City University, Nagoya, Japan,
Department of Forensic Medicine and Clinical Toxicology, Aswan University, Aswan, Egypt)

Oral Session 8

July 5 (Fri) 11:00 - 11:36 Room 6

Oral Session 8
Chairs: D aigo SUMI (Faculty of Pharmaceutical Sciences, Tokushima Bunri University)
Ami OGURO (Graduate School of Biomedical and Health Sciences, Hiroshima University)
Nano Toxicology
O-26
Investigations of toxicity of aged-polystyrene nanoplastics in co-cultured
11:00 - 11:12
caco-2 cell models
Yuki KITAMURA (Department of Environmental and Preventive Medicine, School of Medicine, Jichi Medical
University)

O-27

11:12 - 11:24

Evaluation of the ability to activate antigen-presenting cells and analysis of
the activation mechanism for various types of zinc oxide nanoparticles
Kazutoshi IIJIMA1, 2 (1Faculty of Engineering, Yokohama National University, 2Institute of Advanced
Sciences, Yokohama National University)

Immuno Toxicology
O-28
Role of CXCL5/CXCR2/LIF/LIFR Signaling in Enhancing Immunosuppression
11:24 - 11:36
and Neuroendocrine Differentiation in Prostate Cancer
Yen-Nien LIU (Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science andTechnology, Taipei Medical University)

e57

Program3

Oral Session 9

July 5 (Fri) 11:00 - 11:36 Room 7

Oral Session 9
Chairs: C hiyomi KUBO (Chugai Pharmaceutical Co., Ltd.)
Miyuki IWAI-SHIMADA (National Institute for Environmental Studies)
Immuno Toxicology
O-29
Comparison of age-related changes in immune function and pathology in a
11:00 - 11:12
mouse model of allergic contact dermatitis between senescence-accelerated
mouse prone1 mice and usual aging mice
Mao KANEKI (Laboratory of Veterinary Pharmacology, Graduate School of Veterinary Medicine, Azabu
University)

Clinical Toxicology
O-30
Reactive blue 2 staining is applicable for evaluating male reproductive
11:12 - 11:24
toxicity
Satoshi YOKOTA1, 4 (1Division of Cellular & Molecular Toxicology, Center for Biological Safety & Research,
4

National Institute of Health Sciences, Department of Histology, Graduate School of Medical Sciences, Kumamoto
University)

O-31

11:24 - 11:36

Exploring the Utility of Tissue-Specific cfDNA Methylation Patterns as
Toxicity Markers for Detecting Drug-Induced Testicular Toxicity
Daisuke SASAKI (Astellas Pharma Inc.)

Program

Oral Session 10

July 5 (Fri) 14:00 - 15:00 Room 5

Oral Session 10
Chairs: Maki TOKUMOTO (School of Pharmacy, Aichi Gakuin University)
Fumiyo SAITO (Division of Toxicology, Faculty of Veterinary Medicine, Okayama University of Science)
Clinical Toxicology
O-32
Evaluation of Cardiotoxicity Risk Associated with Tyrosine Kinase Inhibitors
14:00 - 14:12
Using Large-scale Databases
Yusuke IGAWA1, 2 (1Department of Pharmacy, Okayama University Hospital, 2Department of ClinicalPharmacology and Pharmacy, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama
University)

O-33

14:12 - 14:24

Extracellular Vesicle Small RNAs Secreted from Mouse Amniotic Fluid
Induced by Repeated Oral Administration of VPA to Pregnant Mice
Ryuichi ONO (Division of Cellular & Molecular Toxicology, Center for Biological Safety and Research (CBSR),
National Institute of Health Sciences (NIHS))

Regulation Toxicology
O-34
The prediction of activation states of molecular pathways related to
14:24 - 14:36
epithelial-mesenchymal transition and coronavirus
Shihori TANABE (Division of Risk Assessment, National Institute of Health Sciences)
Developmental Toxicology
O-35
Comparative studies between thalidomide and bisphenol A on transcriptome
14:36 - 14:48
profiles using pluripotent stem cells
Hideko SONE (Yokohama University of Pharmacy)

e58

O-36

14:48 - 15:00

Prenatal exposure to Poly(I:C) in mice embryos induces behavioral
abnormalities correlated with abnormal brain morphogenesis anddevelopmental disorders
Munekazu KOMADA (Department of Life Science, Faculty of Science and Engineering, Kindai University)

Oral Session 11

July 5 (Fri) 14:00 - 14:48 Room 6

Oral Session 11
Chairs: Akio SUMIOKA (Department of Basic Medical Sciences, National Institute for Minamata Disease)
Gi-Wook HWANG (Laboratory of Environmental and Health Sciences, Faculty of Pharmaceutical Sciences,
Tohoku Medical and Pharmaceutical University)

O-38

BDNF specifically expressed in hippocampal neurons is involved inmethylmercury neurotoxicity resistance
Masatake FUJIMURA (National Institute for Minamata Disease)

O-39

Study on cell type-specific cytotoxicity and its mechanism of expression
induced by copper phenanthroline complexes
Takehiro NAKAMURA (Fac. Pharm. Sci., Setsunan Univ.)

O-40

Chronic exposure to arsenic causes sarcopenic obesity in humans
Seiichiro HIMENO1, 2 (1Showa University, School of Pharmacy, 2Tokushima Bunri University, School of

14:12 - 14:24

14:24 - 14:36

14:36 - 14:48

Program

Metallomics Toxicology
O-37
Continuous Zn2+–H2O2 toxic signaling in dopaminergic neurodegeneration
14:00 - 14:12
and its protection by unique phenanthrenes of Juncus effusus
Atsushi TAKEDA (School of Pharmaceutical Sciences, University of Shizuoka)

Pharmaceutical Sciences)

Oral Session 12

July 5 (Fri) 14:00 - 15:00 Room 7

Oral Session 12
Chairs: Yuhji TAQUAHASHI (Division of Cellular and Molecular Toxicology, CBSR, National Institute of Health Sciences)
Yuri KATO (Department of Physiology, Graduate School of Phamaceutical Sciences, Kyushu University)
Organ Toxicology
O-41
Valproic acid decreases the expression level of placental tryptophan
14:00 - 14:12
transporter through HDAC inhibition
Kazuma HIGASHISAKA1, 2, 3 (1IACS., Osaka Univ., 2Grad. Sch. Pharm. Sci., Osaka Univ., 3Sch. Pharm.
Sci., Osaka Univ.)

O-42

14:12 - 14:24

Bleomycin causes senescence and lung cytotoxicity, but does not directly
cause fibrosis~Evaluation of cytotoxicity and fibrosis in precision-cut lung slices, PCLS~
Satoshi KANAZAWA (Department of Neurodevelopmental Disorder Genetics, Nagoya City University
Graduate School of Medical Sciences)

O-43

Generation of low adsorption device for engineered cardiac tissue
Yuya FUJIWARA1, 4 (1Center for iPS cell Research and Application, Kyoto University, 4T-CiRA Project)

O-44

Impact on liver pathology via novel targets of SREBP-1
Noriko KEMURIYAMA (Dept. Nutr. Sci. Food Safety, Facul. Biosci., Tokyo Univ. Agricul.)

14:24 - 14:36

14:36 - 14:48

e59

O-45

14:48 - 15:00

Repeated administration of carbon tetrachloride to iron-overloaded rats
induces severe liver injury with systemic hemorrhage
Takeshi IZAWA (Laboratory of Veterinary Pathology, Osaka Metropolitan University)

Oral Session 13

July 5 (Fri) 15:00 - 16:12 Room 7

Oral Session 13
Chairs: Yasumitsu NISHIMURA (Department of Hygiene, Kawasaki Medical School)
Ikuko MIYAZAKI (Department of Medical Neurobiology, Okayama University Graduate School of Medicine,
Dentistry and Pharmaceutical Sciences)

Organ Toxicology
O-46
An activation of MAPK pathway is associated with the suppression of sebum
15:00 - 15:12
production by a BRAF inhibitor, dabrafenib, in hamster sebocytes in vitro
Toshikazu KOIWAI (Department of Biochemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo,
Japan)O-47

A possible mechanism of sebaceous hyperplasia by cyclosporine thataugments sebum production and cell proliferation in hamster sebocytes
in vitro
Tatsuya HOJO (Department of Biochemistry, Tokyo University of Pharmacy and Life Sciences)

O-48

Creation and application of a novel high-throughput individualized zebrafish
nephrotoxicity screening system
Toshio TANAKA1, 2 (1Department of Systems Pharmacology, Mie University Graduate School of Medicine,

15:12 - 15:24

15:24 - 15:36

Program2

Mie University Medical Zebrafish Research Center)

O-49

Regulatory mechanisms of MMP and TIMP-1 expression by uremic toxins,
indoxyl sulfate, in human dermal fibroblasts
Ryousuke TOMITA (Department of Biochemistry, Tokyo University of Pharmacy and Life Sciences)

O-50

Effects of thiamine supplementation on type 2 diabetes status in leptinreceptor deficient mice
Yuka KOHDA (Department of Pharmacotherapeutics and Toxicology, Faculty of Pharmacy, Osaka Medical and

15:36 - 15:48

15:48 - 16:00

Pharmaceutical University)

Food Toxicology
O-4
Development of a bidirectional mass transfer device with food component
16:00 - 16:12
ratio modulation function
Tomofumi FUJINO (School of Pharmacy, Tokyo University of Pharmacy and Life Sciences)e60

Poster Session
P-●E: Candidates for the Excellent Presentation Award
P-●S: Candidates for the Student Poster Award

Day 1 (July 3 (Wed) 17:30 - 18:30) Poster&Exhibition Room

Agricultural Toxicology
P-1E

Mechanisms of disturbance of microglia-neuron interactions induced by
fipronil metabolites
Tetsushi HIRANO (Faculty of Pharmaceutical Sciences, University of Toyama)

P-2S

Evaluation of the Aromatic Hydrocarbon Receptor (AhR) Activation Potential
by Sensitizer-Related Compounds in Waste Paper Recycling Effluent
Jiayan i. SUN (Laboratory of Toxicology, School of Veterinary Medicine, Kitasato University)

P-3E

Molecular mechanisms underlying anti-ferroptotic role of methylglyoxal
Takuya NIIJIMA (Lab. of Health Chem., Grad. Sch. of Pharmaceut. Sci., Tohoku Univ.)

P-4S

Pharmacological activation of TRPC6 channels improves heart failure
Chenlin SU (Graduate School of Pharmaceutical Sciences, Kyushu University)

P-5S

Involvement of TRPC3-Nox2 complex formation in the progression of
striated muscle atrophy
Di WU (Department of Physiology Graduate School of Pharmaceutical Sciences, Kyushu University)

P-6S

Analysis of lipid peroxidation process in ferroptosis and contribution of
CYP7A1Kei ISHIDA (Laboratory of Molecular Biology and Metabolism, Graduate School of Pharmaceutical Sciences,

P-7S

Metabolomic changes of human hepatoma HepG2 cells under cold stressAyano FUKUDA (Graduate School of Medicine and Pharmaceutical Sciences, Chiba University)

P-8S

The effects of gut microbial reactive sulfur species  on the antioxidant
capacity of host and bacteria
Jun UCHIYAMA1, 2 (1Faculty of Pharmacy, Keio University, 2Clinical Research Institute for Clinical

Tohoku University)

Pharmacology and Therapeutics, Showa University)

P-9S

Synergistic effect of retinoids on the antitumor effect of photodynamic
therapy in human glioblastoma cells
Shun KOUNO (Department of Environmental Health, School of Pharmacy, Tokyo University of Pharmacy and

P-10E

Analysis of the role of acyl-CoA synthetase long-chain family member 4 indrug-induced lung injury
Yuki TOMITSUKA (Division of Health Chemistry, Department of Healthcare and Regulatory Sciences, School

Life Sciences)of Pharmacy, Showa University)

e61

Program（Poster）

Redox Toxicology

P-11E

Improvement of exercise endurance in mice through hydrogen water intake:antioxidant effects and metabolic improvements
Eika MIZUNO (Doctoral Program in Medical Sciences, University of Tsukuba)

P-12S

Supersulfide metabolism participates in regulating cardiomyocyte
morphology
Liuchenzi ZHOU1, 2 (1Department of Cardiocirculatory, National Institute of Physiological Sciences, 2Life
Science Research, The Graduate University for Advanced Studies)

P-13S

Mitochondrial ROS and dynamin-related protein 1 mediates angiotensin IIinduced Ca2+ signaling in vascular smooth muscle cells
Yoon-Seok SEO (BK21 FOUR Team and Integrated Research Institute of Drug Development, College of
Pharmacy, Dongguk University, Republic of Korea)

Human Toxicology
P-14S

The impact of long-term exposure to low levels of arsenate on erythropoietin
production in vitro and in vivo
Md. Anamul HAQUE (Laboratory of Toxicology, Faculty of Veterinary Medicine, Osaka Metropolitan
University)

Drug Toxicology
P-15E

A quantitative risk assessment of linezolid-associated thrombocytopenia
based on pharmacokinetic/toxicodynamic simulation
Tetsushu ONITA (Department of Pharmacy, Shimane University Hospital)

P-16E

Mechanism analysis of vancomycin-induced kidney injury focused on
macrophages and circadian rhythm
Taiki FUKUDA (Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu
University)

Program（Poster）

P-17E

Visualization of brain distribution of a benzimidazole analog, metonitazene,
in mouse after intraperitoneal administration using desorption electrosprayionization-mass spectrometry imaging (DESI-MSI)
Sakiko NOMURA (Department of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Instituteof Public Health)

P-18E

Multi-Omics approach to identifying gender differences in cisplatin excretionmechanisms in the proximal tubules of the kidney
Satoshi SHIMIZU1, 2 (1Department of Bio-informational Pharmacology, School of Pharmaceutical Sciences,
2

University of Shizuoka, Center for SI Medical Research and Department of Laboratory Medicine, The Jikei
University School of Medicine)

P-19E

Mechanism of bile acid-dependent hepatocyte death by cccDNA modulator
with IFNα-like activity
Akinori TAKEMURA (Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba
University)

P-20E

Discovery of novel factors responsible for cisplatin renal damage using
cisplatin-resistant proximal tubular cells
Hiroki TAGUCHI (Laboratory of Molecular Nutrition and Toxicology, Graduate School of Pharmaceutical
Sciences, Tokushima Bunri University)e62

P-21E

Exploring the advantages and limitations of Zwitterionic Ionic Liquids (ZIL)
as a novel solvent in in vitro toxicity testing
Yusuke KUBOTA (Suntory Holdings Limited)

P-23E

Comparison of a methods for detecting human mesenchymal stem cells
in mouse tissues in non-clinical studies using quantitative PCR and
immunohistochemical staining
Yuriko YATSUSHIRO (CMIC Pharma Science)

P-24S

Influence of environmental toxicants on avian gut microbiome
Kohei OGASAWARA (Laboratory of Toxicology, Department of Environmental Veterinary Sciences, Facultyof Veterinary Medicine, Hokkaido University)

Food Toxicology
P-25S

Analysis of the exacerbation mechanism of chronic kidney disease (CKD)
cardiomyopathy through abnormal intestinal IgA secretion via vitamin A
accumulation
Kohei FUKUOKA (Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu

P-26S

Regulatory mechanism of phosphorus homeostasis in uninephrectomized
mice fed a high phosphorus diet
Nodoka KAGAMI (Department of Food and Nutritional Science, Graduate School of Agriculture, Tokyo

University)

University of Agriculture)

P-27S

Comprehensive search for novel lysine acyl modifications derived from
L-theanine
Kohei KAWAHARA (Laboratory of Cell Signaling, School of Life Sciences, Tokyo University of Pharmacy

P-28E

A comprehensive toxicological assessment of trans-fatty acids (TFAs) for
application to prevention and treatment of TFA-related diseases
Shinnosuke KIMURA (Lab. of Health Chem., Grad. Sch. of Pharmaceut. Sci., Tohoku Univ.)

P-29S

Exploration of lysine acyl modifications derived from food ingredients
Komei AOKI1, 2 (1School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, 2Biomolecular
Characterization Unit, RIKEN Center for Sustainable Resource Science)

Neuro Toxicology
P-30S

Study on the protective effect of amorphous formula of curcuminon maternal imidacloprid exposure-induced disruptive hippocampal
neurogenesis in rats
Yuri EBIZUKA (Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology)

P-31S

Effects of maternal exposure to imidacloprid on cerebellar development andbehaviors of rat offspring
Xinyu ZOU1, 2 (1Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology,
2

Cooperative Division of Veterinary Sciences, Graduate School of Agriculture, Tokyo University of Agriculture andTechnology)

P-32E

AI-based abnormal behavior detection models in cynomolgus monkeys
Hiroya KONNO (Medichianl Safety Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd.)

e63

Program（Poster）

and Life Sciences)P-33S

The hypoalgesia-specific sensory impairment in MeHg-exposed rats is not
associated with peripheral neural degeneration
Misaki OZAWA1, 2, 5 (1HIROO GAKUEN Senior High School, 2Department of Environmental Health, School
5of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Keio Global Science Campus/JST)P-34S

The association between inflammatory-related cells and neurodegenerationin dorsal root ganglion of MeHg-exposed rat
Yuka SEKIGUCHI (Department of Environmental Health, School of Pharmacy, Tokyo University of Pharmacy
and Life Sciences)

P-35E

Separation of neuronal and astrocytic signals for drug toxicity evaluation in
the central nervous system
Hideaki KURASHIKI (Department of Electronics, Graduate School of Engineering, Tohoku Institute ofTechnology)

P-36E

Quantitative 3D image analysis of cell death or microglia dynamics in larvalzebrafish brain to test neurotoxicity
Mizuki YUGE (Department of Integrative Pharmacology, Mie University Graduate School of Medicine)

Organelle Toxicology

Program（Poster）

P-37S

Expression of proteoglycan core proteins and that of their mRNAs are
independently regulated in cultured vascular endothelial cells under hypoxic
conditions
Misaki SHIRAI1, 3 (1Faculty of Pharmaceutical Sciences, Toho University, 3JSPS Research Fellow)

P-38S

Alteration of proteoglycan expression in human vascular endothelial
EA.hy926 cells under hypoxic conditions
Haruka AKIMOTO (Faculty of Pharmaceutical Sciences,Toho University)

P-39S

STAT1 phosphorylation is induced via epigenomic regulation by dithianon
Hirotaka ITO (Department of Medicinal Pharmacology, Faculty of Pharmaceutical Sciences, Graduate School of

P-40S

ATP potentiates hydrogen peroxide toxicity via P2Y receptors in vascularendothelial cells
Rina TSURUTA (Department of Environmental Health, Faculty of Pharmaceutical Sciences, Toho University)

P-41S

Suppression of Perlecan Expression via P2Y2R-Akt signaling Mediated by
ATP in vascular Endothelial Cells
Lihito IKEUCHI (Faculty of Pharmaceutical Science, Tokyo University of Science)

P-42S

Variation in mRNA expression of glycosaminoglycan synthase in vascularendothelial cells under hypoxic conditions
Yutaka MINAGAWA (Department of Environmental Health, Faculty of Pharmaceutical Sciences, Toho

Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University)

University)

P-43E

The role of hiPSC-derived cardiomyocytes in cardiac safety pharmacology
study: NEXEL’s Cardiosight®-S and CiPA assay
Ami KIM (Department of Commercializing iPSC Technology, Division of Drug & Cell Cooperative Relation,
NEXEL Co., Ltd., Korea.)e64Genetic Toxicology
P-44E

Early detection of hepatocarcinogens in rats using γ-H2AX and stem cellmarkers
Mizuho UNEYAMA (Division of Pathology, National Institute of Health Sciences)

P-45E

An indicator of ovulation time in cynomolgus monkeys by ultrasonography
and efforts to improve pregnancy rate
Erise SUGATA (Drug Safety Research Laboratories, Shin Nippon Biomedical Laboratories, Ltd.)

P-46S

Investigation of nuclear receptor CAR-mediated transcriptional control of
Gadd45b through demethylation of Gadd45b gene promoter
Aki TAKESHITA (Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of
Shizuoka)

P-47S

Regulation of mRNA expression in nasal septum cells via epigenomicchanges induced by nitric oxide
Shizuki KAMIUEZONO (Department of Medicinal Pharmacology, Faculty of Pharmaceutical Sciences,
Okayama University)

P-48E

Activation of inflammatory responses via inhibition of DNA methylation byenvironmental electrophile 1,2-Naphthoquinone
Tomoki TSUCHIDA (Department of Medicinal Pharmacology, Faculty of Pharmaceutical Sciences, Graduate
School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University)

P-49S

Comparison of estrogen genotoxicity between mouse Bhas42 and human
MCF-7 cells
Kohei SUGIHARA (Azabu University)

P-50E

Investigation of the involvement of chromosomal rearrangements in thehepatocarcinogenic process of acetamide in rats
Yohei YAMAGAMI1, 2 (1Division of Pathology, National Institute of Health Sciences, 2Laboratory of

P-51S

The cigarette smoke induced attenuation of SLCO2A1 expression is throughAryl hydrocarbon receptor (AhR) activation
Melody N. SHUMBA (Laboratory of Molecular Pharmacokinetics, School of Pharmacy Takasaki University
of Health and Welfare)

Environmental Toxicology
P-52E

Fundamental study on removal of cadmium using bagasse from aquatic
environments
Kaito YAMASHIRO1, 2 (1Department of Environmental Health, School of Pharmacy, Tokyo University of2

Pharmacy and Life Sciences, Laboratory of Public Health, Faculty of Pharmacy, Kindai University)

P-53E

Evaluation of estrogenic activity at low doses of bisphenol A using a novelin vivo detection method
Keishi ISHIDA (Laboratory of Hygienic Chemistry and Molecular Toxicology, Gifu Pharmaceutical University)

P-54S

Investigation into the intracellular dynamics of micro- and nanoplastics
Wakaba IDEHARA (Sch. Pharm. Sci., Osaka Univ.)

P-55S

Mechanisms of DNMT1 -mediated disturbance of neural functions by
methylmercury exposure
Ayu OKUDA (Laboratory of Medical Therapeutics and Molecular Therapeutics, Gifu Pharmaceutical University)

e65

Program（Poster）

Veterinary Toxicology, Tokyo University of Agriculture and Technology)P-56S

Activation of EGFR-ERK signaling by 1,2-naphthoquinone
Yuexuan PAN (Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry, andPharmaceutical Sciences, Okayama University)

P-57S

Species differences between humans and rats in the responsiveness of thenuclear receptor PXR to phenolic antioxidants
Makoto KATSUME (Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama

P-58S

Transcriptional regulation of an adhesion-related gene by organotins via theretinoid X receptor in Mytilus galloprovincialis
Asuka NOMURA (Gifu Pharm. Univ.)

P-59E

Comparative Assessment of Co-Exposure Effects of the Ferruginous
Components of Subway and Ambient PM with Lipopolysaccharide on
Vascular Function
Oluwatoyin Hannah OWOKONIRAN (Division of Environmental Health, Graduate School of Global

University)

Environmental Studies, Kyoto University, Kyoto, Japan)

Chrono Toxicology
P-60E

The Relationship Between Heart Failure And Alteration of Circadian Clock in
Monocyte: A Novel Cardio-renal Interaction
Yuya YOSHIDA (Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu
University)

P-61S

Involvement of Cry2 against cisplatin-induced renal toxicity in mice
Shintaro TORIMOTO (Department of Pharmacy, Gifu University of Medical Science)

Pharmacol. Toxicology
Program（Poster）

P-22E

Construction of an In Vitro Vascular Tolerance Testing System
Yuki YAMAMURO (Chugai Pharmaceutical Co., Ltd., Translational Research Div.)

P-62E

Development of a compound Ames mutagenicity prediction system that
includes information on mutagenicity strength
Satoshi SUGIYAMA (Imaging & Informatics Laboratories, ICT Strategy Division, FUJIFILM Corporation)

P-63S

Prediction of drug permeability using human iPS cell-derived brain capillary
microvascular endothelial cells
Hiroyuki SATO (Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City
University)

P-64E

Development of read-across method derived from toxicity-specificspace using machine learning technology: Example of multi-class skinsensitization risk assessment
Takaho ASAI (Safety & Analysis, R&D Support, Sunstar Inc.)

P-65S

The impact of SMILES representation inconsistencies in the operation ofchemical language models for QSAR prediction
Yosuke KIKUCHI (Graduate School of Pharmaceutical Sciences, The University of Tokyo)

P-66S

Pharmacological and toxicological evaluations of various adjuvantscombined with norovirus VLPs
Juan ZHANG (Kyushu University - Graduate School of Pharmaceutical Sciences - Physiology)e66

P-67S

Large-Scale Study of the Myocarditis Risk in Children After COVID-19
Vaccination
Sakura HIGASHI (Department of Clinical Pharmaceutics, Okayama University)

P-68S

Development of an in silico model to predict the increase of blood alanine
aminotransferase in mice by gapmer antisense oligonucleotide
Kotaro SUZUKI (Regulatory Science, Graduate School of Pharmaceutical Sciences, Nagoya City University)

P-69E

Development of an Artificial Neural Network Model for Risk Assessment of
Skin Sensitization using ADRA
Kosuke IMAI (SHISEIDO CO., LTD. Brand Value R&D Institute)

P-70E

Establishment of an evaluation system for gastrointestinal toxicity using
human intestinal organoids
Yuki SUDO (Translational Research Division, CHUGAI PHARMACEUTICAL CO., LTD.)

P-71S

Constructing Predictive Models for Myocarditis Induced by Immune
Checkpoint Inhibitors
Reina YAMAMOTO (Department of Medicinal Pharmacology, Faculty of Pharmaceutical Sciences, Graduate

P-72S

Analysis of Megalin-Mediated Kidney Injury Using 3D-RPTEC Cell Model
Hanwei PENG (Faculty of Pharmaceutical Sciences, Institute of Medical Pharmaceutical and Health Sciences,

School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University)

Kanazawa University)

P-73S

Development of machine learning models to predict drug-induced liver injury
from various biomedical bigdata
Shogo MOMOKITA (Department of Creative Informatics, Graduate School of Computer Science and Systems

P-74E

Correlation analysis between structural similarities and NOEL differencesin repeated dose toxicity with Hazard Evaluation Support System Integrated
Platform (HESS) database
Shota NAKAGAWA (Kao Corporation, Safety Science Research)

P-75S

Study on heart rate variability indexes for Safety Pharmacology assessmentsof drug-induced undesirable effects on the central nervous systems
Yoshiyasu NAGASHIMA (Department of Veterinary Pathophysiology and Animal Health, The University ofTokyo)

P-76S

Evaluating the Impact of Gastric Acid Suppressants on the Efficacy and
Safety of Dasatinib Using Prescription Data
Maki KAMEOKI (Department of Clinical Pharmaceutics, Okayama University)

P-77S

Measurement of Drug Responses in Acute Mouse Brain Slices Using
Simultaneous Recording of Extracellular Potentials and Electrochemical
Signals with Microelectrode Array System
Aiko HASEGAWA (Department of Electronic Engineering, Graduate School of Engineering, Tohoku Institute

P-78E

Drug evaluation using Human pluripotent stem cell derived cardiomyocyte
under updated ICH E14/S7B
Eueun KIM (Department of Commercializing iPSC Technology, NEXEL Co., Ltd)of Technology)

e67

Program（Poster）

Engineering, Kyushu Institute of Technology)

P-79E

Four-week time-course analysis of the pathogenesis of atopic dermatitis
model induced by MC903 repeated topical application in mice
Yuya HOSHINO (Department of Investigative Toxicology, Preclinical Research, Tokushima Research Center

P-80S

Establishment of a novel chemical carcinogenesis model using rat bladderorganoids
Yuko NAGASHIMA (Laboratory of Veterinary Pharmacology, Tokyo University of Agriculture andfor Drug Discovery, Otsuka Pharmaceutical Co., Ltd.)Technology)

P-81S

Development of a microfluidic device and organoid-based system forevaluation of anticancer drug sensitivity and side effects
Yuki KOBAYASHI (Lab. of Veterinary Pharmacology, Dept. of Veterinary Medicine, Faculty of Agriculture,
Tokyo University of Agriculture and Technology)

P-82S

A Novel Therapeutic Strategy for Diabetic Retinopathy by Using the Dual
PARP-VEGFR Inhibitor
Tai-Ju HSU (Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical
University, Taipei, Taiwan, R.O.C.)

Program（Poster）

P-83S

Reversing the epithelial-mesenchymal transition by histone deacetylase
inhibitor against diabetic retinopathy progression
Yen-Ju CHAN (School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan, R.O.C.)

P-84S

Therapeutic Effect of Aza-PBHA Through Regulated A2E-related Dry AgeRelated Macular Degeneration in ARPE-19 Cell and Mice Retina
Yu-Ting CHU (School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan, R.O.C.)

P-85S

Exploring the Protective Effects of Azatyrosine-Phenylbutyric Hydroxamides
under Blue Light Exposure-induced Geographic Atrophy throughComplement Inhibition
En-Pei SU (School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan, R.O.C.)

P-86S

The Development of Medicinal Fungi Cordyceps cicadae and Hericium
erinaceus in The Therapeutic Application of Blue Light-Induced Age-related
Macular Degeneration
Nien-Nien CHEN (School of Pharmacy, College of Pharmacy, Taipei Medical University)

P-87S

Assessment of platelet activity and thrombogenic potential in soluble
epoxide hydrolase-null mice
Jae-Hyeong KIM (BK21 FOUR Team and Integrated Research Institute of Drug Development, College of
Pharmacy, Dongguk University)

P-88S

Drug library screening identifies NOX2 inhibitor with in vivo efficacy
Yoon-Seok SEO (BK21 FOUR Team and Integrated Research Institute of Drug Development, College of
Pharmacy, Dongguk University, Republic of Korea)

P-89E

Assessment of genotoxicity and carcinogenic potential of animal-based
traditional Chinese medicine
Yun-Rong TSAI (Master Degree Program in Toxicology, College of Pharmacy, Kaohsiung Medical University)

Nano Toxicology
P-90S

e68

Evaluation of Toxicity of Silver Nanoparticle on Male Reproductive Capacity
Yuma SAEKI (Sch. Pharm. Sci., Osaka Univ.)

P-91S

Preparation of fluorescent nanoplastics for kinetic analysis
Mii HOKAKU (Sch. Pharm. Sci., Osaka Univ.)

Immuno Toxicology
P-92S

Development of a method to enhance cancer immunity by microcurrent
stimulation targeting the circadian clock system of macrophages
Fumiaki TSURUSAKI (Department of Pharmacokinetics, Graduate School of Pharmaceutical Sciences,
Kyushu University)

P-93S

Exploring peptides from human herpes virus which related with the
HLA-B*58:01-mediated oxyprinol-induced idiosyncratic adverse effectNanami MITSUYAMA (Graduate School of Pharmaceutical Sciences, Nagoya City University, Regulatory
Science)

P-94S

Development of the regression model in machine learning to predict skinsensitization intensity and considerations for improving interpretability
Juri TOKUNAGA (Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Nagoya

P-95S

Selenium metabolic remodeling triggered by nitric oxide produced ininflammatory macrophages
Hayato TAKASHIMA (Laboratory of Molecular Biology and Metabolism, Graduate School of Pharmaceutical

City University)

P-96E

Real-world surveillance of immune checkpoint inhibitor-induced immunerelated adverse events and their impact on survival outcomes
Ryosuke MATSUKANE (Kyushu University Hospital, Department of Pharmacy)

P-97S

Comparative study of the induction and enhancement of lung inflammation
by different types of environmental particles
Wei LIU (Graduate School of Engineering, Kyoto University)

P-98S

Effects of personal care product particulates on a murine atopic dermatitis
model
Binyang QIU (Graduate School of Engineering, Kyoto University)

Clinical Toxicology
P-99S

Screening for compounds that inhibit chronic kidney disease-induced
cardiac inflammation and fibrosis
Miyu SAKUGAWA (Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu
University)

P-100S Drug structure design by deep learning to avoid hepatotoxicity
Kenshin GOTO (Biochemical Information Engineering Research Department, Graduate School of Information
Engineering, Kyushu Institute of Technology)

P-101S Prediction by non-clinical toxicity studies for gastrointestinal adverse events
caused by small molecule drugs
Masaru SAITO (Department of Pharmaceutical Sciences, International University of Health and Welfare)e69

Program（Poster）

Sciences, Tohoku University)

Regulation Toxicology
P-102S Construction and Evaluation of a High-Performance Ames Prediction Model
Using a Combination of Image Recognition and Molecular Description
Methods Based on 3D Molecular Structures
Yuma IWASHITA (Department of Medical Molecular Informatics, Meiji Pharmaceutical University)

Developmental Toxicology
P-103S Effects of Fetotoxic Chemicals on the BeWo Cell Syncytialization Process
Wakako OKUNO (Sch. Pharm. Sci., Osaka Univ.)
P-104S Elucidation of the function of amino acid transporter SLC6A19 during
placental syncytialization process
Momoe SERIZAWA (Sch. Pharm. Sci., Osaka Univ.)
P-105S Effects of paternal exposure to methylphenidate on the next generation in
Balb/c mice
Kanata AKAIKE (Department of Toxicology, Showa University Graduate School of Pharmacy)
P-106S Developmental Toxicity Assessment Using Human iPSCs by AutomatedMeasurement of FGF Signaling Disruption
Kashu MIZOTA1, 3 (1Faculty of Engineering, Yokohama National University, 3Division of Cellular & Molecular
Toxicology, Center for Biological Safety & Research, National Institute of Health Sciences)P-107S Comprehensive Assessment of Pharmacovigilance: Drug-Induced
Developmental Toxicity Insights from the VigiBase Individual Case Safety
Reports Database
Tomoya KOMASAKA (Department of Medical Molecular Informatics, Meiji Pharmaceutical University)
P-108S Effects of Intrauterine Blood Flow Insufficiency on Brain Development: A
Cross-Understanding for Developmental Neurotoxicology
Saki FUJIMURA (Division of Toxicology and Health Science, Faculty of Pharmaceutical Sciences, SanyoProgram（Poster）

Onoda City University)

P-109S Assessment of maternal immune activation-induced neurodevelopmental
effects on a neuronal differentiation tracer mouse model
Moeka NAGAHIRA (Gifu Pharm Univ)
P-110S Assessment of the early developmental toxicity of chlorinated paraffinsusing human iPSCs
Islem BOUKARA (Center for Marine Environmental Studies, Ehime University, Japan)

Metallomics Toxicology
P-111E Mechanism of cadmium-induced migration and invasion inhibition in
extravillous trophoblast HTR-8/SVneo
Shoko OGUSHI (Laboratory of Public Health & Preventive Pharmacology Faculty of Pharmaceutical Sciences,
Setsunan University)

P-112S Arsenite suppressed Thrombomodulin protein expression in vascularendothelial cells via ERK1/2 pathways activation
Ryoya TOKORO (Department of Environmental Health, Faculty of Pharmaceutical Sciences, Toho University)
P-113S Effect of arsenite on PAI-1 expression in macrophage-like cells - analysis ofdifferent macrophage types Natsumi SASA (Department of Environmental Health, Faculty of Pharmaceutical Sciences, Toho University)e70

P-114S Evaluation of enzyme activity of selenosugar synthase by speciation
analysis
Karin TAKAHASHI (Graduate School of Medicine and Pharmaceutical Sciences, Chiba University)
P-115S Defense Response against Arsenite Toxicity via ATF-4 Activation in VascularEndothelial Cells
Tomohiro TAJIMA (Department of Environmental Health, School of Pharmacy, Tokyo University of Pharmacy
and Life Sciences)P-116S 4-Phenylbutyrate inhibition of methylmercury-Induced neuronal cell death
Ryohei MIKI (Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry, andPharmaceutical Sciences, Okayama University)

P-117S Contribution of claudin-5/ZO-1 to cadmium-induced endothelial cytotoxicity
Tatsuya YAMAGISHI (Department of Environmental Health, Faculty of Pharmaceutical Sciences, Toho
University)

Organ Toxicology
P-118S Recapitulation of IBD pathophysiology and evaluation of its drug efficacy
using colon organoids
Fuki YOKOI (Center for iPS Cell Research and Application (CiRA), Kyoto University)
P-119E Reversible and monitorable nephrotoxicity in rats by the novel potent
transcriptional enhanced associate domain (TEAD) inhibitor, K-975
Hironori OTSUKI1, 2 (1Toxicological Research Laboratories, Kyowa Kirin Co., Ltd., 2Laboratory of Molecular
Toxicology, School of Pharmaceutical Sciences, University of Shizuoka)

P-120S Analysis of the relationship between blood levels of Mac-2 binding protein(Mac-2bp) and hepatic lesion in a mouse model of NASH
Ryohei KAMINO (Department of Food and Nutritional Science, Graduate School of Agriculture, Tokyo

Shizuoka)

P-122S Transcriptome analysis of cultured human vascular endothelial cells after
γ-ray irradiation and correlation analysis with ATP, ADP, and adenosine assecondary soluble factors
Miyabi KOBAYASHI (Faculty of Pharmaceutical Sciences, Tokyo University of Science)
P-123S Phathophysiological roles of macromolecular complex of IKs channels duringsepsisYuma SUZUKI (University of Shizuoka Department of Bio-informational Pharmacology)
P-124E Elucidation of the liver pathophysiology of progressive familial intrahepaticcholestasis using patient-derived iPS cells
Sayaka DEGUCHI (Center for iPS Cell Research and Application, Kyoto University)
P-125S Establishment of a mouse drinking water model of liver injury using
4,4'-methylene dianiline and evaluation of toxicity profile
Takumi IWASAKA (Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences,
The University of Tokyo)

e71

Program（Poster）

University of Agriculture)

P-121S Mechanism for centrilobular hepatocyte hypertrophy: Analysis using gene
expression data and machine learning
Kazuki IKOMA (Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University ofP-126E Establishment of gall bladder organoid derived from cholestericcholelithiasis model mouse and its application
Haru YAMAMOTO (Laboratory of Veterinary Pharmacology, Tokyo University of Agriculture andTechnology)

P-127S Pathophysiological analysis of repeated dose toxicity study of Ethyl
Carbamate (EC;Urethane) in mice
Sayaka OHASHI (Division of Nutritional Science and Food Safety, Department of Applied Biosciences, Tokyo
University of Agriculture)

P-128S Fibroblast growth factor 23 exacerbates myocardial hypertrophy induced by
non-alcoholic steatohepatitis
Yuma NONOSHITA (Department of Veterinary Pharmacology, Graduate School of Agriculture and Life
Sciences, The University of Tokyo)

P-129S Echinochrome prevents sulfide catabolism-associated chronic heart failure
after myocardial infarction in mice
Xiaokang TANG1, 2, 3 (1National Institute of Natural Sciences, National Institute for Physiological Sciences,
2

Division of Cardiocirculatory Signaling, National Institutes of Natural Sciences, Exploratory Research Center on
3Life and Living Systems (ExCELLS), Cardiocirculatory Dynamism Research Group, The Graduate University for
Advanced Studies, School of Life Science, Department of Physiological Sciences)

P-130S Quantitative relationships between the LOEL values for hepatotoxicity andcytochrome P450-inhibitory activity of chemical substances
Nana UCHIDA (Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of
Shizuoka)

P-131S Association analysis of CYP1A1 inhibition with hepatotoxicity using theresults of rat repeated-dose toxicity study of pesticides
Minami SHIBATA (Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of
Shizuoka)

Program（Poster）

P-132E Relationship between immunohistochemical changes of vimentin in Sertoli
cells and spermatogenic defects
Hirokatsu SAITO (Division of Cellular and Molecular Toxicology, Center for Biological Safety and Research,
National Institute of Health Sciences)

Day 2 (July 4 (Thu) 17:15 - 18:00) Poster&Exhibition Room

Agricultural Toxicology
P-133

Novel in vitro eye irritation screening test for Agrochemical formulations
Yoshitaka KAWARAI (Kyoyu Agri Co., Ltd.)

P-134

Understanding species differences in drug susceptibility based on protein
3D structures: A case study on VKOR
Kazuki TAKEDA1, 2 (1Laboratory of Toxicology, School of Veterinary Medicine, Kitasato University,
2

P-135

e72

Department of Computer Science, Tokyo Institute of Technology)

Evaluation of neurotoxicity and prediction of mechanism of action for
insecticides in MEA measurement of human iPS cell-derived neurons
Naoki MATSUDA (Tohoku Institute of Technology)

Redox Toxicology
P-136

Essential Oils Derived from Okinawan Plants Protect Oxidative StressInduced Mitochondrial Dysfunction in Human Skin Cells
Naoki IMAIZUMI (Laboratory of Clinical Physiology, School of Health Sciences, Faculty of Medicine,
University of the Ryukyus)

P-137

Effects of environmental chemical exposure on gut bacteria via protein
chemical modification
Hanako AOKI (Showa University Clinical Research Institute for Clinical Pharmacology and Therapeutics)

P-138

Effect of falcarindiol on hydrogen sulfide-induced cytotoxicity in PC12 cells
Tomokazu OHNUMA (School of Pharmacy, Tokyo University of Pharmacy and Life Sciences)

P-139

Evaluation of Cardiotoxicity by Anticancer Drugs Focusing on Mitochondrial
Function
Moe KONDO1, 2 (1Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences,2

Kyushu University, Fukuoka, Japan, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka,
Japan)

Food Toxicology
P-140

Recent trends in developments and regulatory systems in other countries
regarding food safety of the so-called “cultured meat”
Toshime IGARASHI (Division of Cellular & Molecular Toxicology, Center for Biological Safety & Research,

P-141

Food Biohazard Study for Cell Culture Food 2: Effects of old age on gene
expression in cultured cells and gene variation in biosynthesis/degradationof toxic substances in vivo during passaging
Masatoshi HORI (Laboratory of Veterinary Pharmacology, Department of Veterinary Medical Sciences,

National Institute of Health Sciences)

Graduate School of Agriculture and Life Sciences, The University of Tokyo)

P-142

Program（Poster）

Organelle Toxicology
Effect of long-term treatment with metal compounds on itch mediator
production in keratinocytes
Kazuhiko NISHIMURA (Laboratory of Bioenvironmental Sciences, Department of Veterinary Science,
Graduate School of Veterinary Science, Osaka Metropolitan University)

P-143

Viability evaluation of cultured cells (cell lines, iPS) using a particle counting
analyzer
Yasunori ODA (R&I Business Development, Sysmex Corporation)

P-144

Analysis of mitochondrial susceptibility to hepatotoxicants in aged steatotic
liver
Kazuma HAMADA (Biopharmaceutics and Molecular Toxicology Unit, Faculty of Pharmaceutical Sciences,
Teikyo Heisei University)

P-145

Examination of the involvement of tight junctions in the permeation ofpolystyrene particles in a Caco-2 cell intestinal epithelial model
Hiroshi NAKAGAWA (Laboratory of Toxicology, Graduate School of Veterinary Science, Osaka Metropolitan
University)e73

P-146

Inhibition of proteoglycan synthesis in vascular endothelial cells by carbonylcompounds involved in the generation of advanced glycation endproducts(AGEs)
Takato HARA (Department of Environmental Health, Faculty of Pharmaceutical Sciences, Toho University)

P-147

Cigarette smoke extract-induced mitochondria hyperfission andcardiomyocyte early senescence
Akiyuki NISHIMURA (Division of Cardiocirculatory Signaling, National Institute for Physiological Sciences)

Genetic Toxicology

Program（Poster）

P-148

Developing molecular and computational approaches for detection of
integration of AAV gene therapy constructs
Masanori KOBAYASHI (Pfizer R&D Japan)

P-149

Mode of transmission of F1 sperm DNA methylation changes caused bygestational arsenic exposure to F2 embryos
Keiko NOHARA (Health and Environmental Risk Division, National Institute for Environmental Studies)

P-150

The mechanism of transgenerational epigenetic inheritance induced by arylhydrocarbon receptor and imprinted genes axis
Yukiharu HORIYA (Laboratory of Environmental Epigenetics, Japan)

P-151

Nitrosamines and Carcinogenic Potency: Learnings from Druckrey
Seiji ISHIHARA (Pfizer R&D Japan Drug Safety Research & Development)

P-152

Establishment of mouse esophagus- and forestomach-derived organoids
and their application in chemical carcinogenicity evaluation
Toshio IMAI (Translational Research Division, Central Institute for Experimental Medicine and Life Science)

P-153

Performance of Ames mutagenicity prediction software package xenoBiotic
using quantum chemical calculations
Toshihiko SAWADA (xenoBiotic Inc.)

P-154

Involvement of matrix metalloproteinases in the acquisition of invasive
ability in cells exposed to Thio-dimethylarsinic acidKayoko KITA (Laboratory of Toxicology, Faculty of Pharmaceutical Sciences, Teikyo University)

P-155

Establishing an evaluation system for lung carcinogens thorough intrabronchial administration in rasH2 mice
Ryo INOUE (Central Institute for Experimental Medicine and Life Science)

P-156

Quantification of abasic sites in tissue DNA from estrogen-induced
mammary cancer model ACI/Seg rats
Yoshinori OKAMOTO (Faculty of Pharmacy, Meijo University)

P-157

Differences in the DNA damage responses by environmental particles fromdifferent sources
Raga ISHIKAWA (Graduate School of Global Environmental Studies, Kyoto University)

P-158

Investigation of the mechanisms underlying the sustained bone marrow
suppression induced by DNMT inhibitors
Junya MATSUSHITA (Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd.)e74

Environmental Toxicology
P-159

Effects of bisphenols on the function of sodium/iodide symporter
Masahiro OGAWA (Life & Environment Research Center, Life Science Research Institute, Kumiai Chemical
Industry Co., Ltd.)

P-160

Synthesis and characterization of the magnetic-adsorbents from waste
sugar cane and assessment of its adsorption capability of cesium ions
Fumihiko OGATA (Laboratory of Public Health, Faculty of Pharmacy, Kindai University)

P-161

Investigation of cytotoxic mechanisms of polyvinyl chloride microplastics
Yuya HAGA1, 2 (1Sch. Pharm. Sci., Osaka Univ., 2Grad. Sch. Pharm. Sci., Osaka Univ.)

P-162

Exploration of molecular markers for detection of abnormal Müllerianduct morphology in male Japanese quail embryos exposed to estrogenic
substances
Takehiro SUZUKI (Health and Environmental Risk Division, National Institute for Environmental Studies,

P-163

Protective effect of wheat bran against methylmercury toxicity
Masaaki NAGANO (Department of Basic Medical Sciences, National Institute for Minamata Disease)

P-164

Effects of nickel administration on the reproductive system in female mice
Kenichi KOBAYASHI (National Institute of Occupational Safety and Health, Japan)

P-165

In vitro to in vivo extrapolation (IVIVE) for uterotrophic activity of 4-alphacumylphenol
Mariko MATSUMOTO (Division of Risk Assessment, National Institute of Health Sciences)

P-166

Early detection and mechanism estimation of antithyroid substances byhistopathological and immunohistochemical analyses in 28-day repeateddose toxicity studies in rats
Takeshi TOYODA (Division of Pathology, National Institute of Health Sciences)P-167

Involvement of ferroptosis in methylmercury toxicity and its molecularmechanism
Naoya YAMASHITA (Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University)

P-168

In silico evaluation of TRPA1 activation by fragrance allergens regulated by
the revised EU cosmetics regulation
Toshiko TANAKA-KAGAWA (Yokohama University of Pharmacy)

P-169

Perfluorooctanoic acid stimulates migration of estrogen receptor-negative
breast cancer cells via up-regulation of fatty acid 2-hydroxylase (FA2H), a
PPARα-regulated gene
Koki KANAMEDA (Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University)

Chrono Toxicology
P-170

Chronotoxicity of hepatic and renal toxicity by copper in mice
Hiroki YOSHIOKA (Department of Pharmacy, Gifu University of Medical Science)

P-171

Study on the circadian rhythm in mice implanted with human stomach
cancer cell lines
Motohide GOTO (Department of Occupational Toxicology, Institute of Industrial Ecological Sciences,
University of Occupational and Environmental Health, Japan.)e75

Program（Poster）

Japan)

Pharmacol. Toxicology
P-172

Challenges in developing a wearable device for rats to contribute to
toxicology research
Ryota TOCHINAI (Graduate School of Agricultural and Life Sciences, The University of Tokyo)

P-173

Development of in silico mutagenicity (Ames test) prediction considering
metabolism
Mika IMAMURA (Safety Evaluation Center, Ecology & Quality Management Division, ESG Division,
FUJIFILM Corporation)

P-174

Investigation of an analysis method for respiratory function in free-moving
mice in safety pharmacology studies
Seiya SHIROZU (Ina Research Inc.)

P-175

Application of Matrix Profile Algorithm for Detecting Abnormalities in
Waveform Data with Repetitive Patterns to Electrocardiograms
Yuhji TAQUAHASHI (Division of Cellular and Molecular Toxicology, CBSR, National Institute of Health
Sciences)

P-176

Evaluation of hepatotoxicity using in vitro 3D liver model (invivoid®) andlong-term liver function maintenanceYasuyuki NAITO1, 3 (1TOPPAN Holdings Inc., 3Joint Research Laboratory (TOPPAN) for Advanced Cell
Regulatory Chemistry)

P-177

Machine learning models for phospholipidosis–inducing drugs incorporatinginteraction mechanism with immobilized artificial membrane
Yukihiro KURODA (Division of Physical Chemistry, Department of Pharmacy, Mukogawa Women's
University)

Program（Poster）

P-178

Read Across Assessment for Potential Leachables Without Toxicological
Data
Masanori HIZUE (DSRD-Tokyo, Pfizer R&D Japan)

P-179

The Safety and Efficacy of Sasa senanensis -containing Traditional Chinese
Medical Supplement, Sou-ga, in dogs
Yuta SHINOHARA1, 2 (1Laboratory of Veterinary Pharmacology, Department of Veterinary Medicine, Faculty2of Agriculture, Tokyo University of Agriculture and Technology, Pet Health & Food Division, Iskara Industry CO.,
LTD)

P-180

Analysis of mechanisms of imatinib-induced ototoxicity using HEI-OC1 cells
Yuji OGURO (Nagahama Institute for Biochemical Science, Oriental Yeast Co., Ltd.)

P-181

Establishing an in vitro complement-activation assessment systemusing serum of humans and monkeys for oligonucleotide therapeutics-Collaborative Study of the Consortium for Safety Evaluation of
Oligonucleotide TherapeuticsManami MIYAKE (Mitsubishi Tanabe Pharma Corporation)

P-182

The relationship between long-term exposure and cardiotoxicity ofanticancer drugs in an in vitro model of human induced pluripotent stem cell
derived cardiomyocytes
Yuto HINATA (Ogino Memorial Laboratory, Nihon Kohden Corporation)

P-183

Simultaneous measurement methods of blood pressure and locomotor
activity in free-moving rats
Tomoko NAGAO (Nissei Bilis CO., LTD)e76

P-184Development of AI model for drug-induced phospholipidosis using kMoL
Yoshinobu IGARASHI (Toxicogenomics-informatics project National Institutes of Biomedical Innovation,
Health and Nutrition)

P-185

Validity of NEP detection performance in in vitro pyrogen test
Kazuto NARITA (Food and Drug Safety Center)

P-186

Precision-cut liver slices from PXB-mouse is an ex-vivo culture model for
drug-induced cholestasis
Mikaru YAMAO (PhoenixBio Co., Ltd.)

P-187

Artificial Intelligence QT Analysis by Generating an Automated ECG
Template in Moxifloxacin-treated Telemetered Cynomolgus Monkeys
Kaoru HATANO (Cardio Intelligence Inc.)

P-188

Case Study on the DASS Evaluation of Fatty Acid Methyl Ester Group Using
Alternative Skin Sensitization Test Methods
Junko MOTOYAMA (Safety Science Research Laboratories, LION Corp.)

P-189

Efforts to enhancing cardiotoxicity evaluation in non-clinical toxicity studies
using echocardiography
Hiroshi MIZUNO (Advanced Biosignal Safety Assessment, Eisai Co., Ltd.)

P-190

Verification of Application Concentration and Correction by Residual
Background Current in hERG Current Measurements in Accordance with ICH
E14/S7B Q&As
Keisuke YAMASHITA (Shin Nippon Biomedical Laboratories, Ltd. Drug Safety Research Laboratories)

P-191

Challenge to develop an in vitro MEA test to predict in vivo seizure risk
Norimasa MIYAMOTO1, 2 (1Advanced Biosignal Safety Assessment, Biopharmaceutical Assessment Unit,
2

Eisai Co., Ltd., Laboratory of Genomics-based Drug Discovery, Faculty of Medicine, University of Tsukuba)

The effects of single or pair housing on cardiovascular parameters incynomolgus monkeys and beagles
Takumi KURANO (Shin Nippon Biomedical Laboratories, Ltd.)

P-193

Case studies of NGRA using developmental internal TTC and PBK model
Shuichi SEKINE (Shiseido Co. Ltd., Brand Value R&D Institute)P-194

Cardiotoxicity evaluation method using HD-CMOS-MEA enables predictionof various mechanisms of drugs
Nami NAGAFUKU (Department of Electronics, Tohoku Institute of Technology)

P-195

Investigative local irritation study of candidate vehicles for intramuscularadministration of poorly soluble compounds
Ayano ISHIDA (Global Drug Safety, Eisai Co., Ltd.)

P-196

Towards a Comprehensive Evaluation of hERG-Trafficking Inhibitors
Through the Integration of Multiple Assay Systems
Masaru TSUBOI (Drug Safety Testing Center Co., Ltd.)

P-197

Evaluation of Contraindicated Drug Responses in Dravet Syndrome Brain
Organoids Utilizing Microelectrode Array
Remi YOKOI (Department of Electrical and Electronic Engineering, Tohoku Institute of Technology)

P-198

Cardiac safety assessment of recombinant spike protein from SARS-CoV-2
Shota YANAGIDA (Division of Pharmacology, National Institute of Health Sciences)

Program（Poster）

P-192

e77

P-199The effect of repeated intracerebroventricular administrations on rats andmice from 3 weeks of age
Masahiro YODA (Ina Research Inc.)

P-200

Consideration of toxicity screening methods for nucleic acid drugs
Hiroyuki KOMATSU (Non-clinical Research Department, CMIC Pharma Science Co., Ltd)

Nano Toxicology
P-201

Cellular responses and influencing factors of cellulose nanofibrils on
alveolar macrophages
Katsuhide FUJITA (Research Institute of Science for Safety and Sustainability (RISS), National Institute ofAdvanced Industrial Science and Technology (AIST))

P-202

Induction of cell death and effects of Rubicon and TFEB in alveolar epithelial
adenocarcinoma cells following exposure to silver nanoparticles
Takamitsu MIYAYAMA (Department of Hygiene and Public Health, School of Medicine, Tokyo Women’s
Medical University)

P-203

A single-dose inhalation exposure study of multi-walled carbon nanotube(NT-7) to mice focused on change of lung burden over time
Satoshi YOKOTA (Division of Cellular & Molecular Toxicology, Center for Biological Safety & Research,
National Institute of Health Sciences)

P-204

Kinetic analysis of silver nanoparticles, including changes in their physicalforms
Kazuya NAGANO (School of Pharmaceutical Sciences, Wakayama Medical University)

Metallomics Toxicology
P-205
Program（Poster）

Arsenite suppresses expression of the anticoagulation molecule
thrombomodulin via the Rho/ROCK pathway in vascular endothelial cells
Tsuyoshi NAKANO (Department of Environmental Health Faculty of Pharmaceutical Sciences, Toho
University)

Organ Toxicology
P-206

New Prebiotics by Ketone Donation
Takumi SATOH (Research Center for the Future of Food and Agriculture, Tokyo University of Technology)

Drug Toxicology
P-207

The angiogenesis-modulating effects of coumarin derivatives
Yau-Hung CHEN (Department of Chemistry, Tamkang University)

P-208

Growth inhibition of cis-3,4-diaryl-α-methylene-γ-butyrolactams in MCF-7
cells
Yau-Hung CHEN (Department of Chemistry, Tamkang University)

P-209

Growth inhibition and toxicity assessments of cis-3,4-diaryl-α-methylene-γbutyrolactams in cultured human renal cancer cells and zebrafish embryos
Yau-Hung CHEN (Department of Chemistry, Tamkang University)

P-210

Safety evaluation of cosmetic ingredients based on East Sea (Sea of Korea)
mudJeong Doo HEO (Korea Insitute of Toxicology)e78

P-211

Validation of Thyroid Disruption Assay Using Zebrafish Embryos
Arantza MURIANA (BBD BioPhenix S.L.U (Biobide))

P-212

On the relevance of human liver microtissues for the detection of hepatoxic
drugs early in the drug development process
Madhu NAG (InSphero Inc)

P-213

Ocular Findings in the Preclinical Studies of Subretinal Ocular Gene Therapy
in Cynomolgus Monkeys
Yongbin ZHANG (JOINN Laboratories)

P-214

Non-toxic postbiotics derived from Pediococcus pentosaceus PHK1 inhibit
angiogenic effect of colorectal cancer
Hyunsook LEE1, 2 (1College of Pharmacy, Duksung Women's University, 2Duksung Innovative Drug Center,
Duksung Women’s University)

Food Toxicology
P-215

The Mechanism of BPA-induced Breast Carcinogenesis and the Explorationof Phytochemicals for Prevention
Yan Qin TAN (Food Science and Technology Program, Department of Life Sciences, BNU-HKBU UnitedInternational College, People’s Republic of China.)

Neuro Toxicology
P-216

Comparison of in vitro differentiation protocols for heavy metal-induced
cytotoxicity in human neuroblastoma SH-SY5Y cells
Jannatul FERDOUS1, 2 (1Department of Veterinary Physiology, Joint Faculty of Veterinary Medicine,2

Kagoshima University, Department of Pharmacology, Bangladesh Agricultural University)

P-217

Embracing Regulatory Compliance: Genetox meets Generation SEND
Charuta Amol BAPAT (Instem Group of Companies)

P-218

Exploring the Impact of Cytochrome P450 Isoforms on the Genotoxicity ofPolygoni Multiflori Radix in the Ames Test: A Comparative Study Between
Rat and Human Liver S9 Metabolic Enzymes
Na Young JEONG (Genetic and Epigenetic Toxicology Research Group, Korea Institute of Toxicology)

Environmental Toxicology
P-219

Developing an avian in ovo assay detecting estrogenic effects as aninternationally standardized test method
Tin-Tin WIN-SHWE (Health and Environmental Risk Division, National Institute for Environmental Studies,

P-220

Transcriptome analysis of wild-type and Nrf2-knockout mice exposed toenvironmental arsenic and roles in hypertension development
Cai ZONG (Faculty of Pharmaceutical Sciences, Tokyo University of Science)

P-221

Effects of exposure to microplastics/ nanoplastics on microglia andastrocytes: the roles of oxidative stress and autophagy
Cai ZONG (Faculty of Pharmaceutical Sciences, Tokyo University of Science)

Japan)

e79

Program（Poster）

Genetic Toxicology

P-222

Hematopoietic Acute Radiation Syndrome (H-ARS) in Rhesus Macaque
Model
Ge DONG (Toxicology Department, SAFE Medical Technology Co., Ltd.)

P-223

Comparative toxicity of eleven bisphenol analogs in the nematode
Caenorhabditis elegans
Yeongyu MOON (Gyeongnam Bio-Health Research Support Center, Gyeongnam Branch Institute, Korea
Institute of Toxicology)

P-224

Protective effects of roselle aqueous extracts on UV-induced zebrafish fin
damageYau-Hung CHEN (Department of Chemistry, Tamkang University)

P-225

New bisphenol A metabolites identified using high-resolution mass
spectrometry and metabolomics-based data processing approachYi-Shiou CHIOU6 (Master Degree Program in Toxicology, College of Pharmacy, Kaohsiung Medical
University)

P-226

Thyroid toxicity investigation of 6:2 chlorinated polyfluoroalkyl ether
sulfonate using FRTL-5 cells and porcine thyroid microsome
Byeong-Cheol KANG1, 2 (1Graduate School of Translational Medicine, Seoul National University College of2

Medicine, Department of Experimental Animal Research, Biomedical Research Institute, Seoul National University
Hospital, Seoul, Korea)

Pharmacol. Toxicology

Program（Poster）

P-227

In vitro analysis of drug-induced neuron degeneration by morphologicaldeep learning on a novel microphysiological system
Xiaobo HAN (Tohoku Institute of Technology)

P-228

Identification and toxicological analysis of a novel DYRK inhibitor forpancreatic cancer treatment through structure-based drug screening
Kai-Cheng HSU (Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science andTechnology, Taipei Medical University, Taipei, Taiwan)

P-229

Biological evaluation and toxicological analysis of a novel CLK inhibitor forcholangiocarcinoma treatment
Shiow-Lin PAN (Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science andTechnology, Taipei Medical University, Taiwan)

P-230

The pharmacological and toxicological study of a novel cyclin-dependent
kinase 8 inhibitor attenuating pulmonary fibrosis symptoms
Chia-Ron YANG (School of Pharmacy, National Taiwan University)

P-231

Assessment of Synergistic Anti-cancer Effects between Cisplatin andDoxorubicin
Gaeun KIM (Molecular and Environmental Toxicology Laboratory, College of Pharmacy, Korea University)

P-232

A novel EGFR/c-MET dual inhibitor TC-N19 induces mixed types of cell deathin colorectal cancer cells
Pei-Ming YANG1, 2 (1Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science2and Technology, Taipei Medical University, PhD Program for Cancer Molecular Biology and Drug Discovery,
College of Medical Science and Technology, Taipei Medical University)e80

Immuno Toxicology
P-233

Cell Irritation Assay Predicts Injection Site Reactions Induced by ParenteralCompounds
Beibei BI (General Toxicity & Genotoxicity Non-Clinical Regulatory Science & Non-Clinical Safety Laboratory
for Drug Discovery and Development SHIONOGI & CO., LTD.)

P-234

Quinovic acid Enhances the Cytotoxicity of the Natural Killer Leukemia Cell
Line KHYG-1 by Increasing the Expression Levels of Granzyme B and IFNgamma Through the NK receptors and MAPK pathway
Yi-Ching CHUANG (Oral Cancer Research Center, Changhua Christian Hospital, Taiwan)

P-235

Subchronic respiratory toxic response following exposure to particles fallingfrom building exterior walls
Eun-Jung PARK (Kyung Hee University)

Regulation Toxicology
P-236

Acute and sub-acute subcutaneous toxicity of PhotoMed®, a novel
photodynamic therapeutic agent in Sprague-Dawley rats
Eun-Sol SEONG2 (Center for Animal Medicine and Foods, Korea Institute of Toxicology)

Developmental Toxicology
P-237

Zebrafish embryos as model for developmental toxicology assessment
Elisabet MATEU HUERTAS (ZeClinics S.L., Spain)

P-238

MSC-derived Exosomes Transferring Mitochondrial Component to Alleviate
Radiation-induced Lung Injury
Kevin Chih-Yang HUANG1, 2 (1China Medical University, 2China Medical University Hospital)

P-239

Infection with SARS-CoV-2 Omicron BA.2.75.2 Exacerbated the Pulmonary
Injury in PHMG-induced Pulmonary Fibrosis Mice
Min-Seok KIM (Inhalation Toxicology Research Group, Korea Institute of Toxicology)

P-240

Effects of Formaldehyde Exposure on Lung Injury and Diabetes in the db/db
Mouse Model
Gyuhwan BAE (Inhalation Toxicology Research Group, Jeonbuk Branch Institute, Korea Institute of Toxicology(KIT))

P-241

Efficient generation of human hepatocyte-like cells from hESC enables drug
discovery and liver regenerative medicine
Chen-Cheng LEE (Aurora Bioscience Co., Ltd.)

Pathological Toxicology
P-242

Development of AI classifiers and integration into a commercially available
decision support tool for toxicologic pathology
Laoise LORD BISSETT (Deciphex)

P-243

Brief case: histopathologic analysis of xenotransplanted primates andcomplication of immunosuppressantsJinhyung RHO1, 3 (1Jeonbuk Pathology Group, Korea Institute of Toxicology, Jeongeup, 3Center for Companion
Animal New Drug Development, Korea Institute of Toxicology, Jeongeup)

e81

Program（Poster）

Organ Toxicology

Day 3 (July 5 (Fri) 13:00 - 13:45) Poster&Exhibition Room

Drug Toxicology

Program（Poster）

P-244

Post-mortem degradation of amlodipine by hemoglobin in blood
Yoshikazu YAMAGISHI (Graduate School of Medicine, Chiba University)

P-245

Analysis of UDP-glucuronosyltransferase 2B7 oligomers: detecting
intracellular higher order forms and exploring cysteine residues involved indisulfide bond formation
Yuu MIYAUCHI (Faculty of Pharmaceutical Sciences, Sojo University)

P-246

Metabolism and toxicity of bosentan in chimeric mice with humanized liver
Shotaro UEHARA (Central Institute for Experimental Medicine and Life Science)

P-247

Development of a Ported Intrathecal Dosing Procedure for Cynomolgus
Monkey Model Using Antisense Oligonucleotide X
Tetsuya YOSHIKAWA (Drug Research Laboratory, Shin Nippon Biomedical Laboratories (SNBL), Ltd.)P-248

The Influence of aldehyde dehydrogenase inhibition on acyclovir
metabolism: in vitro studies
Saki TAKEDA (Department of Forensic Medicine, Fukushima Medical University School of Medicine)

P-249

Novel culture method of human iPS cell-derived intestinal epithelial cells(F-hiSIECTM) for improvement of drug metabolizing ability and potential
application to toxicity evaluation
Seiichi MOCHIZUKI (Bioscience & Engineering Laboratories. FUJIFILM Corporation)

P-250

Background data analysis of rasH2 mice produced by CLEA Japan over a
26-week experimental period (2020–2022)
Masahiko YASUDA (Central Institute for Experimental Medicine and Life Science)

P-251

Study on preparation of a rat crescentic glomerulonephritis model
Toshinori MORITANI (NISSEI BILIS Co., Ltd., Shiga Laboratory)

P-252

Involvement of CYP3A7 in acetaminophen-induced toxicity
Hiroki TERAOKA (School of Veterinary Medicine, Rakuno Gakuen University)

P-253

Development of a selective lung orthotopic model and evaluation of
anticancer drug efficacy using a bronchoscope
Chiyoko NISHIME (Central Institute for Experimental Medicine and Life Science)

P-254

Withdrawal

P-255

Automated detection and classification model of rat bone marrow cell using
deep learning technology
Takashi YAMAGUCHI (Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd.)

P-256

Development of a Mitochondrial Toxicity Prediction AI Model Using In Silico
Predicted Physicochemical Properties
Noriko UCHIYAMA (Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation)

P-257

Investigation of a Method for Measuring Canine Bowel Sound Using an
Electronic Stethoscope
Atsushi NARA (Sunplanet Co., Ltd.)

P-258

Basic study of various APTT reagents in rats and dogs
Nao KIKUGAWA (Otsuka Pharmaceutical Factory, Inc.)e82

Neuro Toxicology
P-259

Absence of functional deficits in rats following systemic administration ofan AAV9 vector despite moderate peripheral nerve and dorsal root ganglion
findings: a clinically silent peripheral neuropathy
Masanori HIZUE (DSRD-Tokyo, Pfizer R&D Japan)

P-260

Behavioral analysis of a mouse model of hypothyroidism using a fully
automated device: a fundamental approach to elucidate the interaction
between chemical exposure and genetic factors
Fumihiko MAEKAWA (National Institute for Environmental Studies)

P-261

Molecular analysis of mice deficient in the stress response transcription
factor ATF5 during cortical development
Mariko UMEMURA (Laboratory of Environmental Biology, School of Life Sciences, Tokyo University of
Pharmacy and Life Sciences)P-262

D-penicillamine had protective effects but not recovery-promoting effects
against diphenylarsinic acid-induced aberrant astrocyte activation
Takayuki NEGISHI (Faculty of Pharmacy, Meijo University)

P-263

Investigating tacrolimus-induced neurotoxicity and ibudilast as a drug
repositioning candidate for neuroprotection
Ryosuke MATSUKANE (Kyushu University Hospital, Department of Pharmacy)

P-264

Time-dependent changes in long-term memory and brain cells in mice
exposed to methylmercury
Ryota YAMAGATA (Division of Environmental Health, Faculty of Pharmaceutical Sciences, Tohoku Medical

P-265

Gene expression analysis in rat brains treated with abusive drugs - Research
for a new evaluation method for drug dependenceErika TAKAHASHI (Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd.)

P-266

Evaluation of drug-induced psychiatric adverse events by evaluation ofsocial behavior of pair-housed dogs living in EURO Guide-compliant cages
Miho MUKAI (Shionogi & Co., Ltd.)

P-267

Functional analysis of synaptic network and single neuron in human iPS
cortical neurons using HD-CMOS-MEA
Yuto ISHIBASHI (Department of Electrical and Electronic Engineering, Tohoku Institute of Technology)

Omics Toxicology
P-268

Elucidation of the mechanism of vascular endothelial hyperpermeability
induced by BCR-ABL inhibitors
Yukari YAMASHITA (Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd.)

Immuno Toxicology
P-269

Elucidation of the pathogenesis of flutamide induced liver injury
Saori TANAKA (Faculty of Pharmacy, Osaka Medical and Pharmaceutical University)

P-270

Daily ascending dosing mitigated cytokine release syndrome induced by
T-cell engager without compromising cytotoxic activity in cynomolgus
monkeys
Yoshika IWATA (Translational Research Division, Chugai Pharmaceutical. Co., Ltd.)
e83

Program（Poster）

and Pharmaceutical University)P-271

Elucidation of immune response control mechanism by endoplasmic
reticulum ATP transporter Slc35b1
Kazuhiro NISHIYAMA (Laboratory of Prophylactic Pharmacology, Osaka Metropolitan University Graduate

P-272

Effects of senescence on the Immune Responses related to sensitization
potential of chemicals
Koji ISHIDA (Laboratory of Veterinary Pharmacology, Department of Veterinary Medicine, Graduate School of

School of Veterinary Science)

Veterinary Medicine, Azabu University)

P-273

Exploration of cytokine release syndrome mechanism by single cell RNAseq analysis using human PBMC treated with alemtuzumab
Ayaka SUGENO (Kyowa Kirin Co., Ltd.)

P-274

Rapid in vitro assessment of the immunogenicity potential of engineered
antibody therapeutics
Yoshiyuki ARATA (Chugai Pharmaceutical, Co., Ltd.)

P-275

Investigation of an in vitro assay for immunogenicity evaluation of antibody
therapeutics targeting immunotherapy
Baekjun PIOR (Translational Research Division, Chugai Pharmaceutical Co., Ltd.)

P-276

Development of the Innate Immune Stimulation Assay for Oligonucleotide
Therapeutics Using Human PBMC - Collaborative Study of the Consortiumfor Safety Evaluation of Oligonucleotide Therapeutics
Kohei IZUSAWA (Sumitomo Pharma Co., Ltd.)

P-277

Comparisons of effects of lipopolysaccharide derived from Escherichia
coli and Porphyromonas gingivalis , a bacterium implicated in periodontal
disease, on blood IL-6, TNF-alpha and IL-10 levels in mice
Tadashi SAIGUSA (Department of Pharmacology, Nihon University School of Dentistry at Matsudo)

Program（Poster）

Clinical Toxicology
P-278

Utility of N-Titin as a skeletal muscle atrophy marker in a mouse model ofskeletal muscle atrophy
Katsunori RYOKE1, 2 (1Toxicology Research Laboratories, Central Pharmaceutical Research Institute, Japan2

Tobacco Inc. , Department of Nutritional Science and Food Safety, Graduate School of Applied Bioscience, Tokyo
University of Agriculture)

P-279

Effect of the additives contained in pharmaceutical formulations on skin
injury caused by extravasation of taxane anticancer drugs
Masaki TAKAISHI (Department of Pharmaceutical Sciences, International University of Health and Welfare)

Regulation Toxicology
P-280

Genotoxicity information collection for developing flavors assessment
schemeAyako FURUHAMA (Division of Genome Safety Science, Center for Biological Safety and Research,
National Institute of Health Sciences)

P-281

Development of gene therapy products
Safety issues and countermeasures in gene therapy using AAV vectors
Yusuke KAGAWA (Novartis Pharma K.K. Preclinical Safety & Pharmacology Group Translational Medicine
Dept.)

e84

P-282Development of a novel off-target evaluation method to assess toxicity at theprotein level
Nobumichi OHOKA (Division of Molecular Target and Gene Therapy Products, National Institute of HealthP-283

Nonclinical safety evaluation of CAR-T cell therapy product: tisagenlecleucel
Yukari FUJIWARA (Preclinical Safety and Pharmacology, Translational Medicine, Novartis Pharma K.K.)

P-284

Update and Compilation of the database of the glossary for nonclinical
toxicity studies ‘Dokuseishiken Yougoshuu ’
Takuya NISHIMURA (National Institutes of Health Science, Center for Biological Safety and Research)

P-285

Considerations for the non-clinical safety assessments of GLP-1 receptor
agonists - Perspective of the reviewers (PMDA)Yuki TAKAHASHI (Pharmaceuticals and Medical Devices Agency)

P-286

INHAND: International Harmonization of Nomenclature and Diagnostic
Criteria - An Update - 2024
Shim-mo HAYASHI1, 2 (1National Institute of Health Sciences, 2Tokyo University of Agriculture andSciences)

P-287

Sample SEND datasets including errors which cannot be detected bystandard validators; the usefulness of the CJUG SEND tool
Akito SAKAMOTO1, 2 (1CDISC Japan User Group(CJUG) SEND team, 2Mediford Corporation)

P-288

Industrial Survey Results and Insights on the Creation and Utilization of
SEND Data Packages
Takayuki YASUDA1, 2 (1CDISC Japan User Group SEND Team, 2Chugai Pharmaceutical Co., Ltd.)

P-289

Repeated Dose 90-Day Oral Toxicity Study of Zirconium(IV) Butoxide in Rat
Yasumasa MURATA (Division of Risk Assessment, National Institute of Health Sciences)P-290

Points to be considered for SEND implementation of genotoxicity study data
based on the SENDIG-Genetox v1.0
Hiroyuki NITTA1, 2 (1CDISC Japan User Group (CJUG) SEND team, 2Ono Pharmaceutical Co., Ltd.)

P-291

Maximum Daily Exposures as Precedent Cases for U.S. Pharmaceutical
Excipients in Comparison with Those for JapaneseMoritake IIJIMA (Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate
School of Medical Sciences and Medical School)

P-292

Determination of SEND Scope with a Flowchart according to FDA's Study
Data Technical Conformance Guide
Chihiro NAKAZAWA1, 2 (1CDISC Japan User Group (CJUG) SEND team, 2Eisai Co., Ltd.)

P-293

Post-COVID Safety Signal Detection from Spontaneous Reporting Systems
Atsushi MIDORIKAWA (WorldFusion Co., Ltd.)

P-294

Regulatory Science Analysis for Increased Use of Microsampling
Kazuaki TAKAHASHI (Mediford Corporation)

P-295

Detailed hazard assessment of ethylbenzene to propose a revised indoor air
quality guideline
Kaoru INOUE (National Institute of Health Sciences)e85

Program（Poster）

Technology)

P-296

Quantitative evaluation of carcinogenicity in Risk Assessment I under theChemical Substances Control Law: Examining the validity of applying unit
risk/slope factor
Kazuo USHIDA (Division of Risk Assessment, National Institute of Health Sciences)P-297

Non-clinical safety assessment for a long-acting LDL cholesterol loweringsiRNA, inclisiran sodium, LEQVIO for s.c. injection syringe 300 mg
Tadayoshi MIKAMI (Preclinical Safety & Pharmacology Group, Translational Medicine Dept, Novartis

P-298

Validation study of pyrogen-detection system using immortalized humanmonocyte cell line
Takao ASHIKAGA (National Insitute of Health Sciences)P-299

Development of an in vitro Assay for Dose Selection in Trans-Tracheal
Intrapulmonary Spraying Administration in Rats
Masaki FUJIOKA (Department of Molecular Pathology, Osaka Metropolitan University Graduate School of

P-300

Screening hazard assessment of 1-nonanol and 1-decanol: A read-acrosswith different chain-length alcohols
Lucia Satiko YOSHIDA-YAMASHITA (Division of Risk Assessment, National Institute of HealthPharma K.K.)

Medicine)

Sciences)

Program（Poster）

P-301

A questionnaire survey on reproductive and developmental toxicity studies
and its alternative assays for pharmaceutical pruducts
Fumito MIKASHIMA (Pharmaceuticals and Medical Devices Agency)

P-302

Changes in gene expression due to product-related impurities of nucleic
acid therapeutics
Kazuya ISHIDA (Chemicals Evaluation and Research Institute, Japan)

P-303

In vivo mutagenicity evaluation of cobalt acetate tetrahydrate
Takako ISO (Division of Risk Assessment, Center for Biological Safety and Research, National Institute of

P-304

Draft guideline for non-clinical safety evaluation of chemically synthesizedpeptide drugs with nonnatural structures
Yoshiro SAITO (National Institute of Health Sciences)

P-305

Developmental neurotoxicity assessment of pyrethroids using human iPSCderived neurons with multi-electrode array system
Yukuto YASUHIKO (Division of Pharmacology, National Institute of Health Sciences)P-306

Development of a risk assessment scheme for leachables from water supply
equipment
Akihiko HIROSE (Chemicals Evaluation and Research Institute, Japan)

P-307

Case of establishment of a SEND data utilizing system through a crossstudy data integration and visualization in a pharmaceutical company
Keigo IKEDA (Sumitomo Pharma Co., Ltd.)

P-308

Development of analytical method for thyroid hormones (T3 and T4) in bloodusing LC-MS/MS
Hiromi NOZAKI (Safety Research Institute for Chemical Compounds Co., Ltd)

Health Sciences)e86

P-309Understanding Changes in SENDIG-DART v1.2 and Exploring SpecificApproaches to Address the Changes
Shin-ichi HORIKAWA (Ina Research Inc.)

Developmental Toxicology
P-310

Reproductive and neurobehavioral effects of combined exposure todinotefuran and synergist in an F1-generation toxicity study in mice: Single
and combined administration based on ADI
Toyohito TANAKA (Division of Toxicology, Department of Pharmaceutical and Environmental Sciences,P-311

Solutions to problems in reproductive and developmental toxicity studies (2)-Development of drugs causing testicular toxicity and analysis of reasonsfor their approvalRyuichi KATAGIRI1, 5 (1Chugai Pharmaceutical Co., Ltd., 5KT2, Non-Clinical Evaluation Expert Committee,

Tokyo Metropolitan Institute of Public Health)Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association)

P-312

Solutions for issues in reproductive and developmental toxicity studies (1)Strategy of Reproductive and Developmental Toxicity Studies for Marketing
Application in Pharmaceutical Development
Takuro OSAWA1, 6 (1Kowa Company, Ltd., 6KT2, Non-Clinical Evaluation Expert Committee, Drug Evaluation

P-313

ex vivo MicroCT and Finite Element Analyses of Trabecular Bone in PediatricFemoral Neck
Yuji ISOBE (Drug Safety Research & Development, Pfizer R&D Japan)

P-314

Developmental Toxicity Assessment Using Human iPSCs Based on the Wnt
Signal Disruption
Rieko MATSUURA (Division of Cellular & Molecular Toxicology, Center for Biological Safety & Research,

P-315

Effect on Testicular Development in Rats by Differences in Timing of γ-ray
Irradiation
Dai YAMAMOTO (Mediford Corporation)

P-316

An attempt to assess developmental neurotoxicity through behavioral
analysis using zebrafish
Mizuho ONO (New Business Development Group, Environmental, Health and Safety Assessment Center,

P-317

Retrospective survey of key toxicological findings related to developmental
neurotoxicity caused by pesticides
Makiko KUWAGATA (Division of Cellular and Molecular Toxicology, CBSR, National Institute of HealthCommittee, Japan Pharmaceutical Manufacturers Association)

Mitsubishi Chemical Research Corporation)

Sciences)

P-318

Animal model of intrauterine hypo-perfusion for understanding thecommonalities of developmental toxicity
Wakana YAMADA (Division of Toxicology and Health Science, Faculty of Pharmaceutical Sciences, SanyoOnoda City University)e87

Program（Poster）

National Institute of Health Sciences)

Metallomics Toxicology
P-319

Novel synthetic approaches and biological functions of selenosugars
Noriyuki SUZUKI1, 3 (1Faculty of Pharmaceutical Sciences, Toho University, 3Graduate School of
Pharmaceutical Sciences, Chiba University)

P-320

Verification of Cell Specificity in Methylmercury Toxicity
Akio SUMIOKA (Department of Basic Medical Sciences, National Institute for Minamata Disease)P-321

Eliminating effect of retinoic acid on cadmium toxicity and gene expression
changes
Jin-Yong LEE (School of Pharmacy, Aichi Gakuin University)

P-322

Diphenylarsinic acid could bind to specific intracellular proteins in cultured
normal rat cerebellar astrocytes
Shoto SASAKI (Department of Pharmaceutical Sciences, International University of Health and Welfare)P-323

Uranium dynamics and localization in established renal tubular cells derived
from S1 to S3 regions
Shino HOMMA TAKEDA (Institute for Radiological Science, National Institutes for Quantum Science andTechnology)

P-324

The association between toxic metal exposure and site-selective biomarkers
of renal injury
Kenta IWAI (Health and Environmental Risk Division, National Institute for Environmental Studies)

P-325

Alteration in protein supersulfide induced by methylmercury in neuronalcells
Takamitsu UNOKI (National Institute for Minamata Disease)

P-326

Role of Nrf2 in Arsenic-induced Endothelial Vascular Toxicity in Vitro Studies
Yusuke KIMURA (Department of Environmental and Preventive Medicine, School of Medicine, Jichi Medical
University)

Program（Poster）

P-327

Protective effects of glutathione on the cytotoxicity of various metalloids in
rat proximal tubular epithelial cells
Maki TOKUMOTO (School of Pharmacy, Aichi Gakuin University)

Organ Toxicology
P-328

Identification of novel PPARγ-regulated microRNAs as involved in hepatic
lipid accumulation
Kohei MATSUO (Faculty of Pharmaceutical Sciences, Department of Pharmaceutical Sciences, Fukuoka
University)

P-329

Evaluation of phenobarbital-induced perturbation of thyroid hormone in wild
type and CAR knockout mice using micro-sampling techniqueJunji YANO (Sumitomo Chemical Co., Ltd.)

P-330

Mouse tracheal epithelial cells in Air-Liquid Interface culture recapitulate invivo responses to long-term cigarette smoke exposure
Kyoko KUSHIBE (Scientific Product Assessment Center, Japan Tobacco)P-331

Development of culture technology and functional evaluation of human liverorganoids
Ai YAMAGUCHI (Life Science Laboratory, Technology and Development Division, Kanto Chemical Co., Inc.)

e88

P-332

Feasibility study on prediction of drug-induced cardiac events using
Multivariate Analysis of the Ca transient in human iPS Cell-Derived
Cardiomyocytes
Atsunori HATTORI (Laboratory for Drug Discovery and Development, Shionogi & CO., LTD.)P-333

The New Medium to Promote Bile Canaliculi Formation without Matrigel
Sandwich Culture
Teruhiko WATANABE (Technology & Development Division, Life Science Laboratory, Kanto Chemical Co.,

P-334

Development of an in vitro co-culture model to evaluate the mechanism ofgastrointestinal toxicity induced by a GUCY2c/CD3 bispecific antibody
Tetsuki KATO (Pfizer R&D Japan)

P-335

Evaluation of skin inflammatory responses with an in vitro three-dimensional
reconstructed skin model containing human-induced pluripotent stem cellderived macrophages
Takahiro YAMAZAKI (KIRIN Central Research Institute, Kirin Holdings Co., Ltd.)P-336

In vitro three-dimensional reconstruction of a model of aged skin withepidermal thinning and lowered barrier function
Yuji MORITA (KIRIN Central Research Institute, Kirin Holdings Co., Ltd.)

P-337

Effects of multiple blood sampling on detection sensitivity for QT
prolongation by moxifloxacin in cynomolgus monkey
Katsuyuki KAZUSA (Astellas Pharma Inc.)

P-338

CD44 expression in an allopurinol-induced rat model of AKI to CKD
Kohei MATSUSHITA (Division of Pathology, National Institute of Health Sciences)P-339

Possible relationship between genetic polymorphisms of phase II drug
metabolizing enzymes (SLUT1E1, NAT2) and liver cancer in Japanese  Yasuna KOBAYASHI (Showa University, School of Pharmacy)

P-340

Comparison of intra-tracheal intrapulmonary spraying (TIPS) and systemic
inhalation methods for classification of poisonous and deleterious
substances in rats
Hirotoshi AKANE (Division of Pathology, National Institute of Health Sciences)

P-341

Quantitative evaluation of drug-induced cholestatic hepatotoxicity using an
in vitro culture model
Mimori YAMADA (Chugai Pharmaceutical Co., Ltd.)

P-342

An exploratory study to establish a method for evaluating gut sound data inmonkeys using an electronic stethoscope
Etsuko OHTA (Global Drug Safety, Eisai Co., Ltd.)

P-343

AI-based CT imaging analysis for drug-induced lung injury in cynomolgus
monkeysKen SAKURAI (Medicinal Safety Research Laboratories, Daiichi Sankyo Co,. Ltd.)

P-344

Examination of co-culture medium of human cryopreserved hepatocytes andengineered heart tissue for a cardiotoxicity evaluation via drug metabolism
Daiju YAMAZAKI (Division of Pharmacology, National Institute of Health Sciences)e89

Program（Poster）

Inc.)P-345

The role of activating transcription factor 5 (ATF5) on lipid droplet formationin mouse liver
Akari URANO (Laboratory of Environmental Biology, School of Life Sciences, Tokyo University of Pharmacy

P-346

Development of the nephrotoxicity evaluation system by nucleic acid drugs
using 3D-cultured human renal proximal tubule epithelial cells
Kaoru MORIMURA (R&D Department, Precision Engineering Center, Industrial Division, Nikkiso Co., Ltd.)

P-347

Strain differences in diet-induced nonalcoholic steatohepatitis conditions inrats
Kinuko UNO (Laboratory of Animal Physiology and Functional Anatomy, Graduate School of Agriculture,

P-348

Development of cardiac contractile function evaluation system by measuring
impedance of human iPS cell-derived cardiomyocytes using a multipoint
electrode array
Reiko HARA (FUJIFILM Corporation)

P-349

Analysis of the mechanism of impaired cadmium reabsorption using rat
proximal tubule-cells
Hitomi FUJISHIRO (Faculty of Pharmaceutical Sciences, Tokushima Bunri University)and Life Sciences)

Kyoto University)

Pathological Toxicology

Program（Poster）

P-350

The strategy of incorporating the histopathological examination into the
Bovine Corneal Opacity and Permeability (BCOP) test: New development for
implementation
Yukie ABIKO (Safety Research Institute for Chemical Compounds Co., Ltd.)

P-351

Development and application of immunostaining database at Conference on
Experimental Animal Histopathology
Takayasu MOROKI1, 2 (1Conference on Experimental Animal Histopathology, 2Department of Drug Safety
Research, Preclinical Research, Tokushima Research Center for Drug Discovery, Otsuka Pharmaceutical Co., Ltd.)Drug Toxicology
P-352

Developing predictive in vitro Glomerulus, Proximal Tubule and Loopof Henle renal cell model platforms to investigate the renal uptake andnephrotoxic liability of Large Molecules
Colin BROWN (Newcells Biotech)

Environmental Toxicology
P-353

e90

Utilization of high-content imaging for the study of lung fibrosis
Colin BROWN (Newcells Biotech)